

NCI

FACT BOOK

**National
Cancer
Institute**

2002

**U.S. DEPARTMENT
OF HEALTH AND
HUMAN SERVICES**

Public Health Service

National Institutes of Health

The information set forth in this publication is compiled and amended annually by the financial management staff of the National Cancer Institute and is intended primarily for use by members of the Institute, principal advisory groups to the Institute and others involved in the administration and management of the National Cancer Program. Questions regarding any of the information contained herein may be directed to the Financial Management Branch, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland, 20892.

TABLE OF CONTENTS

Executive Summary	Fiscal Year 2002 Annual Report.....	iii
Organization	Director's Biography	O-1
	Former Directors of the NCI.....	O-2
	National Cancer Advisory Board.....	O-3
	Boards of Scientific Counselors and Advisors.....	O-7
	President's Cancer Panel.....	O-8
	Executive Committee Members.....	O-8
	NCI Director's Consumer Liaison Group	O-9
	Organization Charts:	
	National Cancer Institute.....	O-10
	Office of the Director	O-11
	OD I: Office of Management	O-12
	OD II: Immediate Office of the Director	O-13
	OD II: Office of the Deputy Director	O-13
	OD II: Center to Reduce Cancer Health Disparities	O-13
	OD III: Office of the Deputy Director for Extramural Science..	O-14
	OD IV: Office of Communications.....	O-15
	OD IV: Office of Science Planning and Assessment.....	O-15
	OD IV: Office of Budget and Financial Management	O-15
	Center for Cancer Research.....	O-16
	Division of Cancer Epidemiology and Genetics	O-18
	Division of Cancer Prevention.....	O-19
	Division of Cancer Control and Population Sciences.....	O-20
	Division of Cancer Treatment and Diagnosis	O-21
	Division of Cancer Biology	O-22
	Division of Extramural Activities	O-23
Cancer Statistics	Number of Deaths for the Five Leading Cancer Sites.....	C-1
	Relationship of Cancer to the Leading Causes of Death in the U.S.....	C-1
	Estimated New Cancer Cases and Deaths	C-2
	The Cost of Cancer.....	C-3
	Average Years of Life Lost Per Person Dying of Cancer.....	C-4
	Five-Year Relative Survival Rates by Cancer Site	C-5
	Cancer Incidence Rates.....	C-6
	Cancer Mortality Rates Changes from 1992 to 1998	C-7
	Cancer Incidence Rates by Race.....	C-8
	Cancer Mortality Rates by Race.....	C-9
	The Prevalence of Cancer	C-10
Budget Data	NCI Budget.....	B-1
	Program Structure.....	B-2
	Extramural Funds	B-3
	NCI Obligations by Mechanism.....	B-4
	Division Obligations by Mechanism.....	B-5
	NIH Management Fund, Service & Supply Fund and GSA Rent...	B-6
	Special Sources of Funds	B-7
	Research Funding for Various Research Areas.....	B-8

Extramural Programs	Research Project Grants:	
	Number of Awards	E-1
	Requested, Awarded.....	E-2
	Awards by Activity Code	E-3
	Activity Code Descriptions	E-4
	Cancer Centers	
	By State	E-5
	Specialized Programs of Research Excellence (SPORE)	E-6
	National Research Service Awards – Pre and Post Doctoral	
	Trainees.....	E-7
	Construction/Renovation Funding	E-8
Grant and Contract Awards by State	E-9	
Grant and Contract Awards by Country.....	E-10	
Institutions Receiving More than \$15,000,000 in NCI Support	E-11	
Historical Trends	Appropriations of the NCI.....	H-1
	Bypass Budget Requests.....	H-2
	Comparison of Bypass Requests and Appropriations of the NCI..	H-3
	Comparison of Dollars, Positions and Space.....	H-4
	Personnel Resources	H-5
	AIDS Funding History.....	H-6

This publication may be viewed on the World Wide Web by pointing a browser to the Financial Management Branch homepage on the National Cancer Institute’s website: www.nci.nih.gov or www.cancer.gov.

Executive Summary

Fiscal Year 2002 Annual Report

BUDGET IN REVIEW

This report provides a summary of the distribution of the Fiscal Year 2002 budget among the various National Cancer Institute (NCI) research programs and funding mechanisms, funding policies influencing grant awards, and comparisons with prior year allocations. Additional information on the NCI budget is accessible from the NCI Home Page (<http://www.cancer.gov>).

Summary

Funds available to the NCI in FY 2002 totaled over \$4.176 billion, reflecting an increase of 11% and \$423 million over the previous fiscal year.

Fiscal highlights from FY 2002 include:

- Of the total NCI budget, 60% of the funds were allocated for Research Grants.
- The total number of Research Project Grants (RPG) funded grew to 4,976.
- Nearly one-fourth of the RPGs awarded were new (Type 1) or competing renewal (Type 2) awards.
- Over 30% of the total NCI budget supported ongoing non-competing (Type 5) RPGs.
- For the third year in a row, R01 grants were funded to the 22nd percentile.
- 374 grants – totaling over \$86 million – were funded as Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards.
- Intramural Research remained at 15% of the total NCI budget in FY 2002.
- Over \$500 million – 12% of the total NCI budget – was allocated for Cancer Prevention & Control.

Distribution of the Budget by Funding Mechanism for FY 2001 and FY 2002

Summary Points

Of the \$423 million increase:

- Almost two-thirds of the increase – or \$272 million – was allocated for the Research Grants budget mechanisms.
- \$197 million – or 47% of the increase – was provided to the Research Project Grant (RPG) category.
- Within the RPG category, \$157 million of the increase was allocated to cover increased expenses for non-competing grants.
- \$42 million – or 10% of the increase – was provided to the Cancer Prevention & Control budget mechanism.
- Funds for training and career development of current and future research scientists through Research Career Awards grew by 7%; Career Education funding increased by 23%.
- The total budget for Cancer Centers, Specialized Centers (U54) and SPOREs increased by 14%. Since the inception of the new grant activity in FY 2001, the funding of Specialized Centers (U54) has increased by 56%.

NCI Dollars by Mechanism for FY 2001 and FY 2002

(Dollars in Thousands)

	2001	2002	Change 01-02	
			Amount	%
Research Project Grants:				
Noncompeting	\$1,166,705	\$1,323,942	\$157,237	13.5%
Admin Supplements	36,831	46,785	9,954	27.0%
Competing	417,233	436,121	18,888	4.5%
Subtotal, RPG	1,620,769	1,806,848	186,079	11.5%
SBIR/STTR	75,833	86,366	10,533	13.9%
Total, RPG	1,696,602	1,893,214	196,612	11.6%
Cancer Centers	192,116	208,009	15,893	8.3%
Specialized Cancer Centers (U54)	10,771	16,847	6,076	56.4%
SPOREs	76,844	94,897	18,053	23.5%
Total; Centers, U54s, SPOREs	279,731	319,753	40,022	14.3%
Research Career Program	51,175	54,867	3,692	7.2%
Cancer Education	21,741	26,775	5,034	23.2%
Clinical Cooperative Groups	154,261	163,826	9,565	6.2%
Other Grants	42,023	58,667	16,644	39.6%
Subtotal, Other	269,200	304,135	34,935	13.0%
Total, Research Grants	2,245,533	2,517,102	271,569	12.1%
National Research Service Awards	57,927	63,674	5,747	9.9%
R&D Contracts	283,971	298,232	14,261	5.0%
Intramural Research	567,298	637,581	70,283	12.4%
Research Management & Support	136,509	153,904	17,395	12.7%
Cancer Prevention & Control	459,482	501,208	41,726	9.1%
Construction	3,000	5,000	2,000	66.7%
Total, NCI	3,753,720 *	4,176,701 **	422,981	11.3%
AIDS research included above	[\$237,789]	[\$254,396]	[\$16,607]	[7.0%]

* Does not include \$4.8 million received by the NCI from the US Postal Service's sale of the Breast Cancer Stamp

** Does not include \$1.1 million received by the NCI from the US Postal Service's sale of the Breast Cancer Stamp

Percent Share of Total NCI Dollars


Summary Points

- The mechanism shares of the total budget remained relatively stable from FY 2001 to FY 2002.
- Although the two largest intramural divisions, DCS and DBS, were consolidated at the end of FY 2001, Intramural Research has remained at 15% of total NCI dollars.

Percent Share of Total NCI Dollars

	1998	1999	2000	2001	2002
Research Project Grants	48.7%	47.1%	46.1%	45.2%	45.3%
Cancer Centers*	5.3%	5.3%	5.1%	5.4%	5.4%
SPOREs	1.2%	1.5%	1.6%	2.0%	2.3%
Clinical Cooperative Groups	3.7%	4.2%	4.4%	4.1%	3.9%
Intramural Research	17.3%	15.5%	15.3%	15.1%	15.3%
R&D Contracts	6.8%	7.4%	7.6%	7.6%	7.1%
Cancer Prevention & Control	9.9%	10.6%	11.8%	12.2%	12.0%
Other Mechanisms	7.1%	8.5%	8.1%	8.3%	8.7%

* FY 2001 and FY 2002 include funds used for Specialized Cancer Centers (U54)



Funding Trends

Summary Points

- The NCI budget has increased by \$1.65 billion – or 65% – since FY 1998.
- All mechanisms, except for Research Project Grants and Intramural Research, have experienced percentage increases greater than the total NCI growth.
- Intramural Research has expanded at the lowest percentage of all mechanisms.

Historical Funding Trends

(Dollars in Millions)

	1998	1999	2000	2001	2002
Total NCI	\$2,527.5	\$2,891.6	\$3,311.1	\$3,753.7	\$4,176.7
Research Project Grants	1,230.8	1,361.8	1,528.0	1,696.6	1,893.2
Intramural Research	437.8	448.2	507.8	567.3	637.6
Cancer Centers*	134.0	153.2	169.1	202.9	224.8
SPOREs	30.9	42.6	52.3	76.8	94.9
Clinical Cooperative Groups	93.0	120.2	144.6	154.3	163.8
Cancer Prevention & Control	249.9	306.3	389.4	459.5	501.2
R&D Contracts	171.1	214.1	251.6	284.0	298.2
Other Mechanisms	180.0	245.2	268.3	312.3	363.0


* FY 2001 and FY 2002 include funds used for Specialized Cancer Centers (U54)

% Growth by Mechanism

	1998 to 1999	1999 to 2000	2000 to 2001	2001 to 2002	1998 to 2002
Total NCI	14.4%	14.5%	13.4%	11.3%	65.3%
Research Project Grants	10.6%	12.2%	11.0%	11.6%	53.8%
Intramural Research	2.4%	13.3%	11.7%	12.4%	45.6%
Cancer Centers*	14.3%	10.4%	20.0%	10.8%	67.8%
SPOREs	37.9%	22.8%	46.9%	23.6%	207.1%
Clinical Cooperative Groups	29.2%	20.3%	6.7%	6.2%	76.1%
Cancer Prevention & Control	22.6%	27.1%	18.0%	9.1%	100.6%
R&D Contracts	25.2%	17.5%	12.9%	5.0%	74.3%
Other Mechanisms	36.2%	9.4%	16.4%	16.2%	101.7%

*FY 2001 and FY 2002 include funds used for Specialized Cancer Centers (U54)

National Cancer Institute
 Historical Funding Trends
 Cumulative Growth



Cumulative Growth

	1998 to 1999	1998 to 2000	1998 to 2001	1998 to 2002
Total NCI	14.4%	31.0%	48.5%	65.3%
Research Project Grants	10.6%	24.1%	37.8%	53.8%
Intramural Research	2.4%	16.0%	29.6%	45.6%
Cancer Centers	14.3%	26.2%	51.4%	67.8%
SPOREs	37.9%	69.3%	148.5%	207.1%
Clinical Cooperative Groups	29.2%	55.5%	65.9%	76.1%
Cancer Prevention & Control	22.6%	55.8%	83.9%	100.6%
R&D Contracts	25.1%	47.0%	66.0%	74.3%
Other Mechanisms	36.2%	49.1%	73.5%	101.7%

Research Project Grants

Summary Points

- 91% of competing dollars supported grants awarded within the established payline; 9% supported grants as an exception to the payline.
- RFA funds, which decreased from the FY 2001 dollar level, accounted for 6% of FY 2002 competing dollars.
- \$4.3 million of funds for Accelerated Executive Review permitted the award of 11 grants.
- Research applications submitted to NCI increased by approximately 6%.

Research Project Grants

(Dollars in Thousands)

	2001*		2002**	
	No.	Amount	No.	Amount
Total funding for RPGs	4,695	\$1,696,602	4,976	\$1,893,214
SBIR/STTR	328	\$75,833	374	\$86,366
Funding for RPGs without SBIR/STTR Program	4,367	\$1,620,769	4,602	\$1,806,848
Continuation or noncompeting grants funded	3,191	\$1,148,844	3,338	\$1,323,942
Competing grants funded	1,176	\$417,233	1,264	\$436,120
Administrative Supplements		\$36,831		\$46,785
Partial assessment for DHHS Program Evaluation		\$17,861		\$45,273
Funds set aside within competing dollars for:				
Grants within Paylines:	1,077	\$373,119	1,148	\$395,013
Traditional R01	759	\$254,218	768	\$247,548
Program Projects (P01)	26	\$46,094	32	\$65,964
RFA Grants	55	\$28,576	34	\$24,987
Share of competing grant funds		6.85%		6.08%
Exception Grants	99	\$44,114	116	\$41,108
Share of competing grant funds		10.57%		9.43%
Competing Application Requests	4,421	\$1,653,483	4,588	\$1,655,392
Funding Success Rate	27%		28%	
Percentile funding for R01 grants	22nd		22nd	
Average Cost-Competing		\$355		\$345
Average Reduction from recommended/requested levels		-16%		-10%


*Does not include \$4.8 million received by the NCI from the US Postal Service's sale of the Breast Cancer Stamp

**Does not include \$1.1 million received by the NCI from the US Postal Service's sale of the Breast Cancer Stamp

Grant Funding Paylines

RPG Mechanisms:	2001	2002	
R01 Traditional Grants	22nd	22nd	percentile
P01 Program Projects	N/A*	N/A*	priority score
R03 Small Grants	225	225	priority score
R21 Exploratory Phase I	200	200	priority score
R33 Exploratory Phase II	170	180	priority score
R41/R42 STTR	237	218	priority score
R43/R44 SBIR	250	279	priority score

* Formal paylines for P01 grants are determined by the Executive Committee



Research Career Awards – “K” Program

Summary Points


- The Research Career Award mechanism grew by 7% in FY 2002.
- Both K04 Research Career Development and K11 Physician Investigator Awards have been completely phased out.
- NCI began using K05 Research Scientist Awards and K25 Mentored Quantitative Career Development Awards in FY 2001. The K05 has doubled in size since its inception in FY 2001. The K25 program is again funding 1 Mentored Quantitative Career Development Award in FY 2002.
- The number of K22 Transition Career Development Awards increased from 8 in FY 2001 to 22 in FY 2002 while funding for these awards nearly tripled.
- NCI’s funding in FY 2002 for the K30 Institutional Curriculum Awards, which are administered by the National Heart, Lung, and Blood Institute, was once again \$1.6 million.

Research Career Awards ("K" Program)

(Dollars in Thousands)

	2001		2002	
	No.	Amount	No.	Amount
K01 Temin Awards	52	\$6,805	58	\$8,427
K01 Minority Mentored Career Development Award	26	3,593	28	3,312
Subtotal, K01s	78	10,398	86	11,739
K05 Research Scientist Award	5	550	10	1,205
K07 Preventive Oncology	57	6,309	75	7,023
K08 Clinical Investigator	124	14,500	134	13,188
K12 Institutional Clinical Oncology Research	21	8,409	11	7,716
K22 Transition Career Development	8	1,190	22	3,359
K23 Patient-Oriented Career	33	4,290	44	4,673
K24 Patient-Oriented Career -- Mid Career	34	3,796	37	4,226
K25 Mentored Quantitative Research Career Development Award	1	133	1	138
	361	49,575	420	53,267
K30 Institutional Curriculum Awards -- Administered by NHLBI	8	1,600	0	1,600
Total Research Career Program	369	51,175	420	54,867

National Cancer Institute
FY 2002
Research Career Awards



Research Dollars by Various Cancers

Summary Points

- Funding for various cancers listed below may overlap
- Funding for cancers listed below do not represent the entire NCI budget

Research Dollars by Various Cancers

(Dollars in Millions)

	1997	1998	1999	2000	2001	2002 Estimate	% Change 01-02
Total NCI	\$2,389.1	\$2,551.3	\$2,891.0	\$3,311.1	\$3,753.7	\$4,176.7	11.3%
Brain & Central Nervous System	46.1	54.3	63.5	71.9	80.7	88.8	10.0%
Breast Cancer	332.0	348.7	387.2	438.7	475.2	535.8	12.8%
Cervical Cancer	55.8	58.0	66.3	67.0	72.6	82.0	12.9%
Colorectal Cancer	103.2	121.0	152.9	175.8	207.4	238.6	15.0%
Head and Neck	38.5	41.9	45.9	47.0	50.0	56.1	12.2%
Hodgkin's Disease	8.1	8.3	8.2	9.4	10.2	11.2	9.8%
Leukemia	91.2	103.4	122.2	141.7	154.0	169.4	10.0%
Liver Cancer	35.3	38.1	39.8	46.2	54.5	62.7	15.0%
Lung Cancer	132.4	139.8	151.0	175.0	206.5	237.9	15.2%
Melanoma	43.3	50.3	60.1	67.9	71.8	77.6	8.1%
Non Hodgkin's Lymphoma	52.7	57.1	66.2	70.4	79.5	89.9	13.1%
Ovarian Cancer	41.7	40.8	56.5	65.5	76.9	88.6	15.2%
Pancreatic Cancer	10.2	14.2	17.3	20.0	21.8	24.6	12.8%
Prostate Cancer	82.3	86.9	135.7	203.2	258.0	291.0	12.8%
Stomach Cancer	9.3	8.2	7.6	6.8	9.0	9.9	10.0%
Uterine Cancer	8.1	12.2	13.8	16.0	18.8	21.6	14.9%

National Cancer Institute

Director's Biography

Andrew C. von Eschenbach, M.D.

Andrew C. von Eschenbach, M.D. is the 12th Director in the 65 year history of the National Cancer Institute. He is a nationally recognized urologic surgeon who formerly directed the Genitourinary Cancer Center and the Prostate Cancer Research Program at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. He also served as special assistant for external affairs to M.D. Anderson's president and held the Roy M. and Phyllis Gough Huffington Clinical Research Distinguished Chair in Urologic Oncology.

A native of Philadelphia, Dr. von Eschenbach received his medical degree from Georgetown University Medical School in 1967. He completed residencies in general surgery and urology at Pennsylvania Hospital in Philadelphia, then was an instructor in urology at the University of Pennsylvania School of Medicine. He served as a Lieutenant Commander in the U.S. Navy Medical Corps.

In 1976, Dr. von Eschenbach went to M.D. Anderson Cancer Center for a fellowship in urologic oncology and was invited to join the faculty the following year. From 1983 to 1996, he was Chairman of the Department of Urology and, since 1985, has also been a Consulting Professor in the Department of Cancer Biology.

In 1996, Dr. von Eschenbach was named the founding director of M.D. Anderson's Prostate Cancer Research Program, comprised of over 60 scientists and clinicians collaborating on integrated translational research in the biology, treatment, epidemiology and prevention of the disease. From 1997 to 1999, he also served as Vice President for Academic Affairs and then as Executive Vice President and Chief Academic Officer, leading a faculty of almost 1,000 cancer researchers and clinicians.

He was a founding member of the National Dialogue on Cancer and, prior to his accepting the position as NCI Director, he was President-elect of the American Cancer Society. Dr. von Eschenbach has contributed more than 200 articles, books and chapters to the scientific literature.

Former Directors of the National Cancer Institute

Richard D. Klausner, M.D.

August 1995 – September 2001

Dr. Klausner was appointed as the Director of the National Cancer Institute (NCI) on August 1, 1995. From 1984 until 1997 he was Chief of the Cell Biology and Metabolism Branch of the National Institute of Child Health & Human Development. Dr. Klausner is well known for his contributions to multiple aspects of cell and molecular biology. Dr. Klausner's research has illuminated the genetics and biochemistry of metals as essential but toxic nutrients for virtually all forms of life, has illuminated the pathways by which molecules traffic and speak to each other within the cell, and has described novel mechanisms by which tumor suppressor genes function.

Samuel Broder, M.D.

December 1988 – March 1995

Dr. Broder joined NCI in 1972 as a Clinical Associate in the Metabolism Branch. In 1981, he became Associate Director for NCI's Clinical Oncology Program. In 1985 he led the laboratory team that discovered the therapeutic effects of AZT and other drugs now approved for the treatment of AIDS including DDI and DDC.

Vincent T. DeVita, Jr., M.D.

January 1980 – June 1980 (Acting)
July 1980 – August 1988

Dr. DeVita joined NCI in 1963 as a Clinical Associate in the Laboratory of Chemical Pharmacology. He served NCI as head of the Solid Tumor Service, Chief of the Medicine Branch, Director of the Division of Cancer Treatment and Clinical Director prior to his appointment as Director of NCI.

Arthur Canfield Upton, M.D.

July 1977 – December 1979

Prior to his tenure as NCI Director, Dr. Upton served as Dean of the School of Basic Health Sciences at the State University of New York at Stony Brook.

Frank Joseph Rauscher, Jr., Ph.D.

May 1972 – October 1976

Dr. Rauscher served as Scientific Director for Etiology, NCI, prior to his appointment as Director of NCI in 1972.

Carl Gwin Baker, M.D.

November 1969 – July 1970 (Acting)
July 1970 – April 1972

During his tenure with PHS, Dr. Baker served as Scientific Director for Etiology, NCI, and as Acting Director of NCI prior to his appointment as Director in July 1970.

Kenneth Milo Endicott, M.D.

July 1960 – November 1969

Dr. Endicott served as Chief of the Cancer Chemotherapy National Service Center, PHS, and as Associate Director, NIH, prior to being appointed Director of NCI in July 1960.

John Roderick Heller, M.D.

May 1948 – June 1960

Dr. Heller joined PHS in 1934 and became Chief of the Venereal Disease Division prior to his appointment as Director of NCI in 1948.

Leonard Andrew Scheele, M.D.

July 1947 – April 1948

Dr. Scheele served in various capacities during his tenure with PHS prior to his appointment as Assistant Chief and, subsequently, Director of NCI in July 1947.

Roscoe Roy Spencer, M.D.

August 1943 – July 1947

Dr. Spencer became NCI's first Assistant Chief and, subsequently, was appointed Director of the Institute in 1943.

Carl Voegtlin, Ph.D.

January 1938 – July 1943

Dr. Voegtlin served as Professor of Pharmacology and Chief of the Division of Pharmacy at the Hygienic Laboratory prior to becoming the first Director of NCI in 1938.

National Cancer Advisory Board

Membership and Term

2004 **Chairperson**

John E. Niederhuber, M.D., Ph.D.

University of Wisconsin School of Medicine
Madison, WI 53792

2004 Elmer E. Huerta, M.D., M.P.H.

Cancer Risk Assess. & Screening Ctr.
Washington Hospital Center
Washington, DC 20010

2006 Samir Abu-Ghazaleh, M.D.

Avera Cancer Institute
Sioux Falls, SD 57105

2004 Susan M. Love, M.D.

Department of Surgery
University of California School of Medicine
Pacific Palisades, CA 90272

2006 James O. Armitage, M.D.

College of Medicine
University of Nebraska Medical Center
Omaha, NE 68198

2006 Arthur W. Nienhuis, M.D.

St. Jude Children's Research Hospital
Memphis, TN 38101

2008 Moon Shao-Chuang Chen, Jr., Ph.D., M.P.H.

University of California
Davis Cancer Center
Sacramento, CA 95817

2004 Larry Norton, M.D.

Medical Breast Oncology
Evelyn H. Lauder Breast Center
Memorial Sloan-Kettering Cancer Center
New York, NY 10021

2008 Kenneth H. Cowan, M.D., Ph.D.

University of Nebraska Medical Center
Eppley Institute for Cancer Research
Omaha, NE 68198

2008 Marlys Popma

Republican Party of Iowa
Des Moines, IA 50309

2008 Jean B. deKernion, M.D.

Department of Urology
UCLA School of Medicine
Los Angeles, CA 90095

2008 Franklyn G. Prendergast, Ph.D., M.A.

Mayo Clinic Cancer Center
Mayo Foundation
Rochester, MN 55905

2004 Stephen C. Duffy

American Academy of Facial Plastic
& Reconstructive Surg. & International
Federation of Facial Plastic Surg. Societies
Alexandria, VA 22314

2004 Amelie G. Ramirez, Dr.P.H., M.P.H.

Department of Medicine
Chronic Disease Prevention
& Control Research Center
Baylor College of Medicine
San Antonio, TX 78230

2006 Ralph S. Freedman, M.B.B.Ch., Ph.D.

Department of Gynecologic Oncology
University of Texas
Houston, TX 77030

2008 Lydia G. Ryan, M.S.N., P.N.P.

Children's Healthcare of Atlanta
AFLAC Cancer Center
Atlanta, GA 30322

2006 James H. French, M.D.

The Center for Plastic Surgery
Annandale, VA 22003

Executive Secretary

Marvin R. Kalt, Ph.D.

Committee Management Officer

Claire Benfer

National Cancer Advisory Board (Continued)

Ex Officio Members

The Honorable Elaine Chao, M.B.A.
Secretary of Labor
Washington, DC 20210

Lester Crawford, D.V.M., Ph.D.
Deputy Commissioner
Food and Drug Administration
Rockville, MD 20857

John Howard, M.D., M.P.H., J.D., LL.M.
Director
National Institute for Occupational
Safety and Health (NIOSH)
Washington, DC 20201

Rachel Levinson
Assistant Director for Life Sciences
Office of Science and Technology Policy
The White House
Washington, DC 20506

Kenneth Olden, Ph. D.
Director
National Institute of Environmental
Health Sciences
National Institutes of Health
Research Triangle Park, NC 27709

Ari Patrinos, Ph. D.
Deputy Director, Office of Biological
and Environmental Research
Office of Energy Research
U.S. Department of Energy
Washington, DC 20585

The Honorable Dr. Robert H. Roswell
Under Secretary for Health
Veterans Health Administration
Department of Veterans Affairs
Washington, DC 20420

Mr. Hal Stratton
Chairman
Consumer Product Safety Commission
Bethesda, MD 20814

The Honorable Tommy G. Thompson
Secretary
Department of Health and Human Services
Washington, DC 20201

The Honorable Christine Todd Whitman
Administrator
Environmental Protection Agency
Washington, DC 20460

The Honorable Dr. William Winkwerder, Jr.
Assistant Secretary of Defense for Health Affairs
Pentagon
Washington, DC 20301

Elias A. Zerhouni, M.D.
Director
National Institutes of Health
Bethesda, MD 20892

National Cancer Advisory Board (Continued)

Alternates to Ex Officio Members

Steven K. Akiyama, Ph.D.
Associate Director for Research and Training
Division of Intramural Research
National Institute of Environmental Health Sciences
National Institutes of Health
Research Triangle Park, NC 27709
(Kenneth Olden, Ph.D. - NIEHS)

Michael A. Babich, Ph.D.
Directorate for Health Sciences
U.S. Consumer Product Safety Commission
Bethesda, MD 20814
(Mr. Hal Stratton - CPSC)

Peter Kirchner, Ph.D.
Program Manager
Office of Biological & Environmental Research
Division of Medical Science
U.S. Department of Energy
Germantown, MD 20874-1290
(Ari Patrinos, Ph.D. - DOE)

Hugh W. McKinnon, M.D., M.P.H.
Associate Director for Health
National Risk Management Research
Laboratory (MD-225)
U.S. Environmental Protection Agency
Cincinnati, OH 45268
(The Honorable Christine Todd Whitman - EPA)

T. G. Patel, M.D., M.A.C.P.
Captain MC USN (Retired)
Program Chief
Veterans Health Administration
Department of Veterans' Affairs
Washington, DC 20420
(The Honorable Dr. Robert H. Roswell - VA)

Richard Pazdur, M.D.
Division Director
Division of Oncology Drugs
Food and Drug Administration
Rockville, MD 20857
(Lester Crawford, D.V.M., Ph.D. - FDA)

John M. Powers, M.D.
Program Director, Quality and
Graduate Medical Education
OASD HA C&PP
Falls Church, VA 22041
(The Honorable Dr. William Winkwerder, Jr. - DOD)

George Ruby, M.D.
Medical Officer
Office of Occupational Medicine
Department of Labor, OSHA
Washington, DC 20210
(The Honorable Elaine Chao - DOL)

Anita L. Schill, Ph.D., M.P.H., M.A., R.N., COHN-S
Senior Scientist
Office of the Director
National Institute for Occupational Safety
and Health
Washington, DC 20201
(John Howard, M.D., M.P.H., J.D., LL.M. - NIOSH)

Note: Bold print represents Ex Officio Members

National Cancer Advisory Board (Continued)

NCAB Subcommittee Assignments

Subcommittee on Activities and Agenda

Dr. John Niederhuber-Chair
Dr. Susan M. Love
Dr. Arthur W. Neinhuis
Dr. Larry Norton
Ms. Marlys Popma
EXECUTIVE SECRETARY: Dr. Marvin Kalt
(301) 496-5147

Subcommittee on Cancer Centers

Dr. Arthur W. Nienhuis - Chair
Dr. James O. Armitage
Dr. Kenneth Cowan
Dr. Ralph S. Freedman
Dr. Elmer E. Huerta
Dr. Larry Norton
Dr. Kenneth Olden (NIEHS, Ex Officio)
Dr. Franklyn Prendergast
Dr. Amelie G. Ramirez
Dr. Phillip A. Sharp (Ex Officio)
EXECUTIVE SECRETARY: Dr. Brian Kimes
(301) 496-8537

Subcommittee on Clinical Investigation

Dr. Larry Norton - Chair
Dr. Jean B. deKernion-Chair
Dr. Samir Abu-Ghazaleh
Dr. James O. Armitage
Dr. Kenneth Cowan
Dr. Lester Crawford (FDA, Ex Officio)
Dr. Ralph S. Freedman
Dr. James H. French
Dr. Elmer E. Huerta
Dr. Susan M. Love
Dr. Franklyn Prendergast
ACTG. EXECUTIVE SECRETARY: Dr. Ellen Feigal
(301) 496-2522

Subcommittee on Special Actions

Dr. Ralph Freedman - Chair
Committee of the Whole
Dr. Phillip A. Sharp (Ex Officio)
EXECUTIVE SECRETARY: Dr. Marvin Kalt
(301) 496-5147

Subcommittee on Planning and Budget

Dr. Larry Norton-Chair
Dr. Moon Shao-Chuang Chen
Dr. Jean B. deKernion
Mr. Stephen Duffy
Dr. Arthur W. Nienhuis
Dr. Franklyn Prendergast
Dr. Amelie G. Ramirez
Dr. Phillip A. Sharp (Ex Officio)
EXECUTIVE SECRETARY: Ms. Cherie Nichols
(301) 496-5515

Ad Hoc Subcommittee on Confidentiality of Patient Data

Dr. Frederick Li - Chair
Ms. Marlys Popma-Chair
Dr. Samir Abu-Ghazaleh
Dr. Jean B. deKernion
Mr. Stephen C. Duffy
Ms. Lydia Ryan
EXECUTIVE SECRETARY: Ms. Mary McCabe
(301) 496-6404

Ad Hoc Subcommittee on Communications

Dr. Susan M. Love - Chair
Dr. Moon Shao-Chuang Chen
Mr. Steven C. Duffy
Dr. James H. French
Dr. Samir Abu-Ghazaleh
Dr. Elmer E. Huerta
Ms. Marlys Popma
Dr. Amelie G. Ramirez
Ms. Lydia Ryan
EXECUTIVE SECRETARY: Ms. Mary McCabe
(301) 496-6404

Ad Hoc Subcommittee on Coding for Research on Minorities

Dr. Frederick Li - Chair
Dr. Elmer Huerta
Dr. Larry Norton
Dr. Amelie G. Ramirez
EXECUTIVE SECRETARY: Ms. Mary McCabe
(301) 496-6404

Board of Scientific Counselors Intramural Programs

Subcommittee 1: Clinical Sciences and Epidemiology

Appointees	Expiration of Appointment	Appointees	Expiration of Appointment
Chair - Michael B. Kastan, M.D., Ph.D.	2004		
Carlos L. Arteaga, M.D.	2004	Daniel M. Medina, Ph.D.	2006
Leslie Bernstein, Ph.D.	2006	Beverly Shriver Mitchell, M.D.	2003
Martin A. Cheever, M.D.	2004	James J. Mule, Ph.D.	2003
Michael L. Cleary, M.D.	2003	Richard J. O'Reilly, M.D.	2005
Deborah E. Collyar, B.S.	2003	Olufunmilayo F. Olopade, MBBS	2004
Chi Van Dang, M.D., Ph.D.	2005	Alice P. Pentland, M.D.	2005
Timothy J. Eberlein, M.D.	2003	Arthur T. Porter, M.D.	2005
Elizabeth T. Fontham, DrPH	2005	David A. Savitz, Ph.D.	2004
Stanley R. Hamilton, M.D.	2006	David T. Scadden, M.D.	2007
Elizabeth A. Holly, Ph.D.	2003	Steven G. Self, Ph.D.	2006
David J. Hunter, MBBS, Sc.D.	2004	Margaret Ann Tempero, M.D.	2004
Laurence N. Kolonel, M.D., Ph.D.	2005	Michael Thun, M.D., M.S.	2005
Frank McCormick, Ph.D.	2003		

Executive Secretary - Abby B. Sandler, Ph.D.

Subcommittee 2: Basic Sciences

Chair - Craig B. Thompson, M.D.	2003		
Rafi Ahmed, Ph.D.	2006	Dan R. Littman, M.D., Ph.D.	2007
Frederick W. Alt, Ph.D.	2005	Guillermina Lozano, Ph.D.	2007
Jon C. Clardy, Ph.D.	2004	Brooke T. Mossman, Ph.D.	2005
Gideon Dreyfuss, Ph.D.	2005	Dinshaw J. Patel, Ph.D.	2005
E. Peter Geiduschek, Ph.D.	2003	Suzanne B. Sandmeyer, Ph.D.	2003
Sankar Ghosh, Ph.D.	2006	Andrey S. Shaw, M.D.	2003
Stephen S. Hecht, Ph.D.	2004	Harinder Singh, Ph.D.	2007
Nouria T. Hernandez, Ph.D.	2006	Ronald I. Swanstrom, Ph.D.	2006
David Housman, Ph.D.	2004	Thea D. Tlsty, Ph.D.	2006
Thomas J. Kelly, M.D., Ph.D.	2004	Gregory L. Verdine, Ph.D.	2004
Richard D. Kolodner, Ph.D.	2005	Cheryl Lyn Walker, Ph.D.	2006
John Kuriyan, Ph.D.	2005	Eileen White, Ph.D.	2005

Executive Secretary - Florence E. Farber, Ph.D.

Board of Scientific Advisors Extramural Programs

Chair - Frederick R. Applebaum, M.D.	2004		
David B. Abrams, Ph.D.	2003	Kenneth W. Kinzler, Ph.D.	2003
David S. Alberts, M.D.	2003	Herbert Y. Kressel, M.D.	2004
Hoda A. Anton-Culver, Ph.D.	2003	Michael P. Link, M.D.	2007
Esther H. Chang, Ph.D.	2003	Lynn M. Matrisian, Ph.D.	2007
Neil J. Clendeninn, M.D., Ph.D.	2005	W. Gillies McKenna, Ph.D.	2004
Tom M. Curran, Ph.D.	2005	Christine A. Miasowski, Ph.D.	2005
Mary Beryl Daly, M.D., Ph.D.	2004	Enrico Mihich, M.D.	2004
Raymond N. Dubois, M.D., Ph.D.	2007	John D. Minna, M.D.	2004
H. Shelton Earp, M.D.	2007	Nancy E. Mueller, Sc.D.	2004
Patricia A. Ganz, M.D.	2007	Richard L. Schilsky, M.D.	2003
Susan B. Horwitz, Ph.D.	2003	Elen V. Sigal, Ph.D.	2003
Hedvig Hricak, M.D., Ph.D.	2007	Margaret R. Spitz, M.D., M.P.H.	2007
William G. Kaelin, M.D.	2005	William C. Wood, M.D.	2004
Paula K. Kim	2007	Robert C. Young, M.D.	2004

Executive Secretary - Paulette S. Gray, Ph.D.

President's Cancer Panel

LaSalle D. Leffall, Jr. M.D. **2004**

Chairman
Charles R. Drew Professor of Surgery
Howard University Hospital
2041 Georgia Avenue, NW, Suite 4000
Washington, DC 20060

Harold P. Freeman, M.D. **2003**

Director of Surgery
North General Hospital
1879 Madison Avenue
Department of Surgery, 5th Floor
New York, NY 10035

Lance E. Armstrong **2005**

Founder, Lance Armstrong Foundation
2901 Bee Caves Road, Suite L
Austin, TX 78746

Maureen O. Wilson, Ph.D.

Executive Secretary

Executive Committee Members

Andrew C. von Eschenbach, M.D.

Director

Alan Rabson, M.D.

Deputy Director

Anna Barker, Ph.D.

Deputy Director for Strategic Scientific Initiatives

Carl J. Barrett, Ph. D.

Director, Center for Cancer Research

Robert Croyle, Ph.D

Acting Director, Division of Cancer Control and
Population Sciences

Ellen Feigal, M.D.

Acting Director, Division of Cancer Treatment
and Diagnosis

Joseph Fraumeni, M.D.

Director, Division of Cancer Epidemiology and
Genetics

Harold P. Freeman, M.D.

Director, Center to Reduce Cancer Health
Disparities

Peter Greenwald, M.D.

Director, Division of Cancer Prevention

John Hartinger

Associate Director for Budget and Finance

Marvin Kalt, Ph.D.

Director, Division of Extramural Activities

Janis Mullaney

Acting Deputy Director for Management

Dinah Singer, Ph.D.

Director, Division of Cancer Biology


Sandy Koeneman, M.S., M.P.A.

Executive Secretary

NCI Director's Consumer Liaison Group


Ms. Barbara K. LeStage, Chair American Cancer Society	2003	Mr. Christopher Pablo Asian and Pacific Islander American	2004
Ms. Vernal H. Branch Y-me National Breast Cancer Organization	2004	Ms. Karen Packer Marshalltown Cancer Resource Center	2004
Ms. Susan Lowell Butler Ovarian Cancer National Alliance	2002	Mr. Henry Porterfield Alliance for Prostate Cancer Prevention	2003
Ms. Kathy Giusti Multiple Myeloma Research Foundation	2004	Ms. Nyrvah Richard Self Help for Women with Breast or Ovarian Cancer (SHARE)	2003
Mr. Michael Katz International Myeloma Foundation	2002	Mr. Doug Ulman Lance Armstrong Foundation	2004
Ms. Ruth Lin, AOCN American Cancer Society	2002	Dr. Marisa Weiss Living Beyond Breast Cancer	2003
Ms. Gena Love People Living Through Cancer, Inc.	2002	Ms. Elaine Lee DCLG Executive Secretary National Cancer Institute Bethesda, MD 20892	

National Cancer Institute




Office of the Director

Director
Dr. Andrew C. von Eschenbach
301-496-5615



Office of Management
 Acting Deputy Director
 Ms. Janis Mullaney
 301-435-2455



Immediate Office of the Director

Director
Dr. Andrew C. von Eschenbach
301-496-5615

Special Assistant for Program Coordination
Ms. Dorothy Foellmer
301-496-5218

Office of the Deputy Director

Deputy Director
Dr. Alan Rabson
301-496-1927

Deputy Director for Strategic Scientific Initiatives
Dr. Anna Barker
301-496-1550

Institute Review Office
Chief
Dr. Maureen Johnson
301-496-7628

Fellowship Office
Chief
Dr. Donna Vogel
301-493-4796

Center to Reduce Cancer Health Disparities

Associate Director
Dr. Harold Freeman
301-594-1027


Deputy Director
Dr. Nadarajen Vydelingum
301-402-6837


Program Analyst
Ms. Dionne Burt
301-594-1027


Disparities Research Branch
Chief
Ms. Barbara Wingrove
301-451-8269

Health Policy Branch
Chief
(Vacant)

Office of the Director Continued - OD III









Center for Cancer Research Office of the Director

Director
Dr. J. Carl Barrett
301-496-4345

Principal Deputy Director
Dr. Kathryn Zoon
301-496-4346

Biostatistics and Data
Management Section
Chief
Dr. Seth Steinberg
301-496-9502





**Division of Cancer Prevention
Office of the Director**

Director
Dr. Peter Greenwald 301-496-6616
Acting Deputy Director
Dr. Leslie Ford
301-496-0265
Associate Director for Clinical Research
Dr. Leslie Ford 301-496-0265

Office of Preventive Oncology
Chief
Dr. Douglas Weed
301-496-8640

**Chemoprevention Agent
Development Research Group**
Chief
Dr. James Crowl
301-496-8563

**Community Oncology and
Prevention Trials Research
Group**
Chief
Dr. Lori Minasian
301-496-8541

**Breast & Gynecologic Cancer
Research Group**
Chief
Dr. Karen Johnson
301-496-8526

**Prostate & Urologic Cancer
Research Group**
Chief
Dr. Howard Parnes
301-594-0920

**Early Detection
Research Group**
Chief
Dr. John Gohagan
301-496-8544

**Biometry Research
Group**
Chief
Dr. Phillip Prorok
301-496-8556


**Gastrointestinal & Other Cancer
Research Group**
Chief
Dr. Ernest Hawk
301-594-2684

**Lung & Upper Aerodigestive
Cancer Research Group**
Chief
Dr. Eva Szabo
301-435-1595

**Nutritional Science
Research Group**
Chief
Dr. John Milner
301-496-8573

**Basic Prevention Science
Research Group**
Acting Chief
Dr. Peter Greenwald
301-496-6616

**Cancer Biomarkers
Research Group**
Chief
Dr. Sudhir Srivastava
301-435-1594



Division of Cancer Treatment and Diagnosis Office of the Director

Acting Director
Dr. Ellen Feigal
301-496-6711

Deputy Director
Dr. Ellen Feigal
301-496-6711

Biometrics Research Branch
Chief
Dr. Richard Simon
301-496-4836

Radiation Research Program
Associate Director
Dr. Norman Coleman
301-496-6111

Radiotherapy Development Branch
Chief
Dr. Francis Mahoney
301-496-9360

Molecular Therapeutics Branch
Chief
Dr. Philip Tofilon
301-496-6336

Clinical Radiation Oncology Branch
Chief
(Vacant)

Cancer Therapy Evaluation Program
Associate Director
Dr. Michael Christian
301-496-6138

Investigational Drug Branch
Chief
Dr. Louise Grochow
301-496-1196

Clinical Investigations Branch
Chief
Dr. Richard Kaplan
301-496-2522

Pharmaceutical Management Branch
Chief
Dr. Carl Huntley
301-496-5725

Regulatory Affairs Branch
Chief
Dr. Dale Shoemaker
301-496-7912

Clinical Trials Monitoring Branch
Chief
Ms. Joan Mauer
301-496-0510

Clinical Grants and Contracts Branch
Chief
Dr. Roy Wu
301-496-8866

Developmental Therapeutics Program
Associate Director
Dr. Edward Sausville
301-496-8720
Deputy Associate Director
(Vacant)

Information Technology Branch
Chief
Dr. Dan Zahareviz
301-496-8747

Biological Testing Branch
Chief
Dr. Joseph Mayo
301-846-5065

Biological Resources Branch
Chief
Dr. Stephen Creekmore
301-846-1098

Toxicology and Pharmacology Branch
Chief
Dr. Joseph Tomaszewski
301-496-8777

Screening Technologies Branch
Chief
Dr. Robert Shoemaker
301-846-1064

Natural Products Branch
Chief
Dr. Gordon Cragg
301-846-5387

Drug Synthesis and Chemistry Branch
Chief
Dr. Ven Narayanan
301-496-8795

Grants and Contracts Operations Branch
Chief
Dr. Mary Wolpert-DeFilippes
301-496-8783

Pharmaceutical Resources Branch
Chief
Dr. Rao Vishnuvajjala
301-496-8780

Cancer Diagnosis Program
Associate Director
Dr. Sheila Taube
301-496-8639

Diagnostics Research Branch
Chief
Dr. Barbara Conley
301-496-1591

Resources Development Branch
Chief
Dr. Roger Aamodt
301-496-7147

Technology Development Branch
Chief
Dr. James Jacobson
301-402-4185

Biomedical Imaging Program
Associate Director
Dr. Daniel Sullivan
301-496-9531

Diagnostic Imaging Branch
Chief
Dr. Edward Staab
301-496-9531

Molecular Imaging Branch
Chief
Dr. John Hoffman
301-496-9531

Image-Guided Diagnosis and Therapy Branch
Acting Chief
Dr. Laurence Clarke
301-496-9531

Imaging Technology Development Branch
Chief
Dr. Laurence Clarke
301-496-9531

**Division of Cancer Biology
Office of the Director**

Director
Dr. Dinah S. Singer
301-496-8636

Deputy Director
Dr. John A. Sogn
301-496-8636

Biological Carcinogenesis Branch

Chief
Dr. Jack Gruber
301-496-9740

Tumor Biology and Metastasis Branch

Chief
Dr. Suresh Mohla
301-435-1878

Chemical and Physical Carcinogenesis Branch

Chief
Dr. David Longfellow
301-496-5471

DNA and Chromosome Aberrations Branch

Chief
Dr. Bruce Wachholz
301-496-9326

Cancer Immunology and Hematology Branch

Chief
Dr. R. Allan Mufson
301-496-7815

Structural Biology and Molecular Applications Branch

Chief
Dr. Daniel Gallahan
301-435-5226

Cancer Cell Biology Branch

Chief
Dr. Colette Freeman
301-496-7028

Division of Extramural Activities
Director, Dr. Marvin R. Kalt
301-496-5147
Deputy Director, Dr. Paulette S. Gray
301-496-4218
Assistant Director, Dr. Cedric W. Long
301-496-9138

Office of Extramural Applications
Associate Director
Dr. Paulette S. Gray
301-496-4218

Office of Referral, Review and Program Coordination
Associate Director
Ms. Diane Bronzert
301-435-5655

Applied Information Systems Branch
Chief
Mr. James W. Seach
301-496-7047

Research Analysis and Evaluation Branch
Acting Chief
Ms. Marilyn Gaston
301-594-1111

Research Programs Review Branch
Chief
Dr. Olivia T. Bartlett
301-594-2501

Special Review and Logistics Branch
Chief
Dr. Kirt J. Vener
301-496-7174

Program Coordination and Referral Branch
Chief
Dr. Ray Bramhall
301-594-1403

Resources and Training Review Branch
Chief
Dr. David Maslow
301-496-2330

Number of Deaths for the Five Leading Cancer Sites by Age Group and Sex

All Ages		Under 15		15-34		35-54		55-74		75+	
Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
Lung & Bronchus 91,397	Lung & Bronchus 63,075	Leukemia 259	Leukemia 204	Leukemia 559	Breast 513	Lung & Bronchus 8,432	Breast 9,347	Lung & Bronchus 51,303	Lung & Bronchus 33,012	Lung 31,530	Lung 24,151
Prostate 32,203	Breast 41,736	Brain & ONS 230	Brain & ONS 195	Brain & ONS 420	Leukemia 383	Colon & Rectum 2,840	Lung & Bronchus 5,791	Colon & Rectum 12,778	Breast 16,845	Prostate 22,123	Colon & Rectum 16,678
Colon & Rectum 28,023	Colon & Rectum 28,950	Endocrine 99	Endocrine 61	NHL 392	Cervix 283	NHL 1,851	Colon & Rectum 2,275	Prostate 9,665	Colon & Rectum 9,838	Colon & Rectum 12,215	Breast 15,031
Pancreas 13,806	Pancreas 14,529	Bone & Joints 49	Soft Tissue 37	Colon & Rectum 189	Brain & ONS 253	Brain & ONS 1,738	Ovary 1,914	Pancreas 6,892	Ovary 6,036	Pancreas 5,249	Pancreas 7,746
NHL 12,205	Ovary 13,390	Soft Tissue 47	Kidney & Renal Pelvis 36	Melanoma 169	NHL 193	Pancreas 1,626	Cervix 1,763	NHL 5,182	Pancreas 5,675	NHL 4,736	NHL 5,950

Source: National Center for Health Statistics (NCHS) Public -use file for 1998 deaths.

NHL = Non Hodgkin's Lymphoma

Relationship of Cancer to the Leading Causes of Death in the United States

Rank	Cause	Number of Deaths	Age Adjusted Rate*	Percent of Total Deaths
	All Causes	2,336,845	645.5	100.0%
1	Heart Disease	724,803	189.0	31.0%
2	CANCER	541,519	161.5	23.2%
3	Cerebrovascular Diseases	158,439	39.4	6.8%
4	Emphysema, Bronchitis & Asthma	112,577	30.9	4.8%
5	Accidents	97,725	31.5	4.2%
6	Pneumonia & Influenza	91,866	21.8	3.9%
7	Diabetes Mellitus	64,751	18.5	2.8%
8	Suicide and Self-Inflicted Injury	30,558	10.0	1.3%
9	Nephritis & Nephrosis	26,182	6.7	1.1%
10	Cirrhosis of the Liver	25,187	8.1	1.1%
11	Septicemia	23,729	6.3	1.0%
12	Alzheimers	22,724	5.0	1.0%
13	Homicide	18,216	6.6	0.8%
14	Aortic Aneurysm	16,237	4.5	0.7%
15	Atherosclerosis	15,279	3.5	0.7%
	Other and Ill-Defined	367,053	102.0	15.7%

Source: NCHS Public-use file for 1998 deaths.

* Age adjusted rate per 100,000 Population

Estimated New Cancer Cases and Deaths by Sex for All Races 2001

Primary Site	Estimated New Cases			Estimated Deaths		
	Total	Male	Female	Total	Male	Female
All Sites *	1,268,000	643,000	625,000	553,400	286,100	267,300
Oral Cavity and Pharynx	30,100	20,200	9,900	7,800	5,100	2,700
Tongue	7,100	4,800	2,300	1,700	1,100	600
Mouth	10,500	6,000	4,500	2,300	1,300	1,000
Pharynx	8,400	6,300	2,100	2,100	1,500	600
Other Oral Cavity	4,100	3,100	1,000	1,700	1,200	500
Digestive System	235,700	124,000	111,700	131,300	70,100	61,200
Esophagus	13,200	9,900	3,300	12,500	9,500	3,000
Stomach	21,700	13,400	8,300	12,800	7,400	5,400
Small Intestine	5,300	2,600	2,700	1,100	600	500
Colon	98,200	46,200	52,000	48,100	23,000	25,100
Rectum	37,200	21,100	16,100	8,600	4,700	3,900
Anus, Anal Canal, & Anorectum	3,500	1,500	2,000	500	200	300
Liver and Intrahepatic Bile Duct	16,200	10,700	5,500	14,100	8,900	5,200
Gallbladder & Other Biliary	6,900	3,200	3,700	3,300	1,200	2,100
Pancreas	29,200	14,200	15,000	28,900	14,100	14,800
Other Digestive	4,300	1,200	3,100	1,400	500	900
Respiratory System	184,600	102,400	82,200	162,500	93,900	68,600
Larynx	10,000	8,000	2,000	4,000	3,100	900
Lung and Bronchus	169,500	90,700	78,800	157,400	90,100	67,300
Other Respiratory	5,100	3,700	1,400	1,100	700	400
Bones and Joints	2,900	1,600	1,300	1,400	800	600
Soft Tissues	8,700	4,600	4,100	4,400	2,100	2,300
Skin (excl. basal & squamous)	56,400	31,700	24,700	9,800	6,300	3,500
Melanomas Of Skin	51,400	29,000	22,400	7,800	5,000	2,800
Other non-epithelial skin	5,000	2,700	2,300	2,000	1,300	700
Breast	193,700	1,500	192,200	40,600	400	40,200
Genital Organs	286,800	206,500	80,300	58,500	32,200	26,300
Cervix Uteri	12,900		12,900	4,400		4,400
Endometrium (uterus)	38,300		38,300	6,600		6,600
Ovary	23,400		23,400	13,900		13,900
Vulva	3,600		3,600	800		800
Vagina and other genital organs, female	2,100		2,100	600		600
Prostate	198,100	198,100		31,500	31,500	
Testis	7,200	7,200		400	400	
Penis and other genital organs, male	1,200	1,200		300	300	
Urinary System	87,500	59,400	28,100	25,000	16,100	8,900
Urinary Bladder	54,300	39,200	15,100	12,400	8,300	4,100
Kidney and Renal Pelvis	30,800	18,700	12,100	12,100	7,500	4,600
Ureter and other urinary organs	2,400	1,500	900	500	300	200
Eye and Orbit	2,100	1,100	1,000	200	100	100
Brain and Other Nervous System	17,200	9,800	7,400	13,100	7,200	5,900
Endocrine Glands	21,400	5,600	15,800	2,300	1,000	1,300
Thyroid	19,500	4,600	14,900	1,300	500	800
Other Endocrine	1,900	1,000	900	1,000	500	500
Lymphomas and Myelomas	63,600	35,000	28,600	27,600	14,500	13,100
Hodgkin's Disease	7,400	3,900	3,500	1,300	700	600
Non-Hodgkin's Lymphoma	56,200	31,100	25,100	26,300	13,800	12,500
Multiple Myeloma	14,400	7,500	6,900	11,200	5,800	5,400
Leukemias	31,500	17,700	13,800	21,500	12,000	9,500
Lymphocytic Leukemias	11,600	6,700	4,900	6,000	3,500	2,500
Myeloid Leukemias	14,700	8,000	6,700	9,500	5,200	4,300
Other Leukemias	5,200	3,000	2,200	6,000	3,300	2,700
All Other Sites	31,400	14,400	17,000	36,200	18,500	17,700

Source: Cancer Facts & Figures-2001, American Cancer Society (ACS), Atlanta, Georgia 2001.
Excludes basal and squamous cell skin and in situ carcinomas except urinary bladder.
Incidence projections are based on rates from the NCI SEER Program 1979-1997.

The Cost of Cancer


Cancer treatment spending has risen but remains stable in proportion to total U.S. treatment spending.

The financial costs of cancer treatment are a burden to people diagnosed with cancer, their families, and society as a whole. Cancer treatment accounted for about \$41 billion in 1995, the most recent year for which there is information. This is just under 5 percent of total U.S. spending for medical treatment. In the 10 years from 1985 to 1995, the overall costs of treating cancer more than doubled.

Year	Amount (in \$ millions)	Percent of All Health Care Expenditures
1963	\$1,279	4.35%
1972	3,872	4.96
1980	13,049	6.01
1985	18,104	4.81
1990	27,458	4.46
1995	41,200	4.69


Source: Brown, ML, Lipscomb J, Snyder C. The burden of illness cancer: economic cost and quality of life. Annual Review of Public Health 2001;22:91-113.

**Average Years of Life Lost
Per Person Dying of Cancer
All Races, Both Sexes, 1998**



Source: NCHS public-use data and 1997 life tables.


5 Year Relative Survival Rates by Site
SEER Program 1992-1997
Males and Females



Data From NCI SEER Program
<http://www.seer.cancer.gov/>


Cancer Incidence Rates

Changes from 1992 to 1998



Cancer Mortality Rates

Annual Percent Changes from 1992 to 2000



Cancer Incidence Rates By Race

SEER, 1992-2000

Cancer Site	Incidence Rates per 100,000				
	Blacks	Whites	Hispanics	Asian/ Pacific Islander	American Indian/ Alaska Native
All Sites	532.0	484.4	355.1	344.6	252.6
Males	724.4	574.3	429.7	401.3	285.1
Females	405.3	427.4	310.5	303.9	231.9
Oral Cavity and Pharynx	13.2	11.2	6.9	9.2	7.8
Esophagus	7.9	4.3	3.2	3.0	3.1
Stomach	14.0	7.9	13.6	18.2	10.5
Colon and Rectum	62.9	54.2	38.6	47.3	35.8
Colon excluding Rectum	48.7	39.3	26.5	32.0	26.0
Rectum and Rectosigmoid Junction	14.2	14.9	12.1	15.2	9.8
Liver and IHBD	6.4	4.4	8.3	13.6	6.8
Pancreas	16.4	10.8	9.8	9.4	7.5
Larynx	7.0	4.1	2.8	1.9	1.3
Lung and Bronchus	83.1	64.4	34.2	43.5	37.0
Males	126.0	83.1	48.3	62.7	51.7
Females	53.9	51.4	24.5	28.4	25.8
Melanoma of the Skin	1.1	18.4	3.9	1.6	2.0
Breast(females)	121.1	138.0	87.8	92.6	60.8
<50 years	44.4	43.0	31.5	37.1	21.1
50+ years	322.0	386.5	235.2	238.0	164.7
Cervix Uteri	13.0	9.5	17.6	11.1	7.2
Corpus and Uterus, NOS	17.7	26.0	16.0	16.7	10.1
Ovary	12.3	18.1	13.9	12.3	11.0
Prostate	286.5	175.4	139.9	106.1	62.9
Testis	1.3	5.9	3.3	2.1	2.5
Urinary Bladder	12.6	22.3	10.6	9.8	4.9
Kidney and Renal Pelvis	12.6	11.1	10.1	6.2	11.2
Brain and Other nervous system	4.0	7.1	4.9	3.5	2.2
Thyroid	3.7	6.6	5.9	7.8	3.8
Hodgkin lymphoma	2.4	3.0	2.3	1.0	^
Non-Hodgkin lymphoma	14.4	20.1	15.8	13.6	7.6
All Sites Except Lung and Bronchus	448.9	420.0	321.0	301.1	215.6
Males	598.4	491.2	381.4	338.5	233.4
Females	351.5	376.0	286.0	275.6	206.1

Data source: NCI SEER Program.

NCI's SEER Program, adjusted to the 2000 US population age distribution.

^ Statistic not shown. Rate based on less than 25 cases for the time interval.

Cancer Mortality Rates By Race United States, 1992-2000

Cancer Site	Mortality Rates per 100,000				
	Blacks	Whites	Hispanics	Asian/ Pacific Islander	American Indian/ Alaska Native
All Sites	263.9	202.9	138.6	128.1	137.2
Males	369.1	256.3	178.3	160.1	170.4
Females	201.3	169.3	112.6	104.0	115.5
Oral Cavity and Pharynx	4.9	2.8	1.9	2.6	2.3
Esophagus	7.7	4.0	2.5	2.2	2.6
Stomach	9.9	4.5	7.5	10.3	5.6
Colon and Rectum	28.9	21.6	14.2	13.7	14.0
Liver and IHBD	5.9	4.0	7.1	10.9	5.5
Pancreas	14.6	10.3	8.4	7.6	6.3
Larynx	3.0	1.4	1.1	0.5	1.1
Lung and Bronchus	68.1	57.4	25.9	29.2	36.9
Males	112.2	80.8	41.5	42.1	52.5
Females	39.3	40.9	14.9	19.2	25.9
Melanoma of the Skin	0.5	3.0	0.8	0.4	0.6
Breast(females)	36.7	28.7	18.1	12.9	14.9
<50 years	11.1	6.3	4.9	4.0	3.2
50+ years	103.6	87.4	52.9	36.2	45.3
Cervix Uteri	6.5	2.8	4.0	3.1	3.3
Corpus and Uterus, NOS	7.0	3.9	3.1	2.2	2.4
Ovary	7.6	9.3	6.2	4.7	4.8
Prostate	75.9	32.5	25.3	15.2	22.9
Testis	0.1	0.3	0.3	0.1	^
Urinary Bladder	4.1	4.5	2.4	1.8	1.5
Kidney and Renal Pelvis	4.2	4.3	3.7	1.9	4.8
Brain and Other nervous system	2.8	5.0	2.9	1.9	2.0
Thyroid	0.4	0.4	0.6	0.7	0.3
Hodgkin lymphoma	0.5	0.6	0.6	0.2	0.2
Non-Hodgkin lymphoma	5.8	8.9	6.6	5.4	4.5
All Sites Except Lung and Bronchus	195.8	145.6	112.7	98.9	100.3
Males	256.9	175.5	136.8	118.0	118.0
Females	162.0	128.4	97.7	84.8	89.6

Data source: NCHS public-use data files.

^ Statistic not shown. Rate based on less than 25 cases for the time interval.

**The Prevalence of Cancer:
Estimated Number of Persons
Diagnosed With Cancer
United States, 1999**

Primary Site	Estimated Prevalence		
	Total ^	Males	Females
ALL SITES	8,928,059	3,929,515	4,998,544
Brain and Central Nervous System	88,614	47,998	40,616
Breast	2,051,280		2,051,280
Cervix	226,232		226,232
Colon and Rectum	1,008,770	483,190	525,580
Corpus and Uterus	533,272		533,272
Esophagus	19,870	14,704	5,166
Hodgkin Lymphoma	117,596	61,385*	56,211*
Kidney and Renal Pelvis	188,104	111,806	76,298
Larynx	93,930	75,835	18,095
Leukemia	166,359	93,169	73,190
Acute Lymphocytic Leukemia	36,650	19,802*	16,848#
Lung and Bronchus	326,895	170,608	156,287
Melanoma of the Skin	440,300	211,800*	228,500*
Non-Hodgkin Lymphoma	289,390	149,051	140,339
Oral Cavity and Pharynx	219,175	141,007	78,168
Ovary	176,663		176,663*
Pancreas	22,742	10,742	12,000
Prostate	1,477,159	1,477,159	
Stomach	63,615	35,889	27,726
Testis	126,015	126,015*	
Thyroid	278,185	63,162	215,023
Urinary Bladder	449,635	330,868	118,767
Childhood (0-19 yrs)	159,356&	82,999&	76,357&

Source: U.S. 1999 cancer prevalence rates are based on 1999 cancer prevalence proportions from the nine SEER registries and 1/1/1999 population estimates based on the average of 1998 and 1999 population estimates from the U.S. Bureau of the Census.

^ The total column represents prevalence estimates using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). Totals are obtained by summing males and females and not by modeling.

*# Completeness index was approximated using empirical data from historical Connecticut tumor registry: *by age at prevalence #for all ages combined due to instability of age specific estimates.

& Current methodology does not allow for the estimation of complete prevalence for childhood cancer

Fiscal Year 2002 Budget

(Dollars in Thousands)

A. Actual Obligations Resulting From Appropriated Funds:

FY 2002 Appropriation	\$4,190,405
Real transfer to other HHS Agencies through Secretary's one percent transfer authority	-4,524
Enacted Rescission	-2,054
Administrative Reduction	-7,118
Lapse	-8
Actual Obligations Subtotal	4,176,701

B. Reimbursable Obligations:


Reimbursements	16,129
-----------------------	---------------

C. Total NCI Obligations: \$4,192,830 *

*EXCLUDES Insight Awards to Stamp Out Breast Cancer(PAR-99-128). In FY 2002, there were 10 R21 awards for \$1,129.

Program Structure Fiscal Year 2002

(Dollars in Thousands)




Budget Activity	Amount	Percent
Research:		
Cancer Causation	\$996,056	23.9%
Detection and Diagnosis Research	294,043	7.0%
Treatment Research	981,787	23.5%
Cancer Biology	656,643	15.7%
Subtotal Research	2,928,529	70.1%
Resource Development:		
Cancer Centers Support	320,651	7.7%
Research Manpower Development	146,249	3.5%
Construction	6,924	0.2%
Subtotal Resource Development	473,824	11.4%
Cancer Prevention and Control	481,272	11.5%
Program Management and Support	293,076	7.0%
*Total NCI	4,176,701	100.0%

*EXCLUDES Insight Awards to Stamp Out Breast Cancer(PAR-99-128). In FY 2002, there were 10 R21 awards for \$1,129.

Extramural Funds Fiscal Year 2002

(Dollars in Thousands)



Mechanism	Amount	Percent
Contracts:		
R&D Contracts	\$277,126	8.6%
Interagency Agreements	21,106	0.7%
Cancer Control Contracts	135,878	4.2%
Construction Contracts	3,500	0.1%
Subtotal Contracts	437,610	13.6%
Grants:		
Research Project Grants	1,893,214	58.6%
Cancer Centers/SPORES	319,753	9.9%
Training Activities	63,674	2.0%
Other Research Grants	304,135	9.4%
Cancer Control Grants	208,209	6.5%
Construction Grants	1,500	0.0%
Subtotal Grants	2,790,485	86.4%
Total Extramural Funds	3,228,095	100.0%
Total Intramural/RMS/Control Inhouse	948,606	
*Total NCI	\$4,176,701	

*EXCLUDES Insight Awards to Stamp Out Breast Cancer(PAR-99-128). In FY 2002, there were 10 R21 awards for \$1,129.

NCI Obligations by Mechanism, Fiscal Year 2002

(Dollars in Thousands)

		Number	Amount	% of Total
Research Project Grants	Non-Competing	3,338	\$1,323,942	31.7%
	Administrative Supplements	(311)	46,785	1.1%
	Competing	1,264	436,121	10.4%
	Subtotal, without SBIR/STTR Grants	4,602	1,806,848	43.2%
	SBIR/STTR Grants-R41-44	374	86,366	2.1%
	Subtotal, Research Project Grants	4,976	1,893,214	45.3%
Centers & SPORES	Cancer Centers Grants-P30	60	208,009	5.0%
	SPORES-P20/P50	43	94,897	2.3%
	U54s	4	16,847	0.4%
	Subtotal, Centers	107	319,753	7.7%
Other Research	Career Program			
	Temin & Minority Mentored Awards-K01	86	11,739	0.3%
	RCDA-K04	0	0	0.0%
	Estab. Inv. Award-K05	10	1,205	0.0%
	Preventive Oncology-K07	75	7,023	0.2%
	Clinical Investigator-K08	134	13,188	0.3%
	Physician Investigator-K11	0	0	0.0%
	Clinical Oncology-K12	11	7,716	0.2%
	Transitional Career Development-K22	22	3,359	0.1%
	Mentored Patient Oriented RCDA-K23	44	4,673	0.1%
	Mid-Career Invest. & Patient Orient. Res-K24	37	4,226	0.1%
	Mentored Quant. Res Career-K25	1	138	0.0%
	Inst. Curr. Award-K30	0	1,600	0.0%
	Subtotal, Career Program	420	54,867	1.3%
	Cancer Education Program-R25	96	26,775	0.6%
	Clinical Cooperative Groups-U10	137	163,826	3.9%
	Biomedical Research Support-S07/S10	0	6,133	0.1%
	Minority Biomedical Support-S06	0	3,980	0.1%
	Scientific Evaluation-U09/T09	1	7,408	0.2%
	Continuing Education	2	204	0.0%
	Resource Grants-R24/U24	65	32,395	0.8%
	Explor Coop Agreement-U56	14	6,558	0.2%
	Conference Grants-R13	81	1,989	0.1%
Subtotal, Other Research Grants	816	304,135	7.3%	
Subtotal, Research Grants		5,899	2,517,102	60.3%
NRSA Fellowships	<i>Trainees:</i>	1,566	63,674	1.5%
R&D Contracts	R&D Contracts	210	294,506	7.1%
	SBIR Contracts	7	2,700	0.1%
	NIH Management Fund		1,026	0.0%
	Subtotal, Contracts	217	298,232	7.2%
Intramural Research	Program	1,930	515,433	12.3%
	NIH Management Fund		122,148	2.9%
	Subtotal, Intramural Research	<i>FTEs:</i>	1,930	637,581
RMS	Research Mgmt and Support	721	139,327	3.3%
	NIH Management Fund		14,577	0.4%
	Subtotal, RMS	<i>FTEs:</i>	721	153,904
Cancer Prevention and Control	Cancer Control Grants	200	208,209	5.0%
	Cancer Control Contracts	173	135,878	3.3%
	Inhouse	466	152,533	3.6%
	NIH Management Fund		4,588	0.1%
	Subtotal, Prevention and Control	<i>FTEs:</i>	466	501,208
Construction			5,000	0.1%
*Total NCI	<i>FTEs:</i>	3,117	4,176,701	100.0%

*EXCLUDES Insight Awards to Stamp Out Breast Cancer(PAR-99-128). In FY 2002, there were 10 R21 awards for \$1,129.


Division Obligations by Mechanisms, Fiscal Year 2002

(Dollars in Thousands)

CCR	DCEG	DCTD	DCB	DCCPS	DCP	DEA	OD	Research Grants	Program Support
								\$1,278,669	\$45,273
								46,785	
								436,121	
								1,761,575	45,273
								86,366	
								1,847,941	45,273
							\$208,009		
		\$216					94,681		
		5,851	\$1,000				9,996		
		6,067	1,000				312,686		
							11,739		
							1,205		
							7,023		
							13,188		
							7,716		
							3,359		
							4,673		
							4,226		
							138		
							1,600		
							54,867		
							26,775		
								163,826	
								6,133	
								3,980	
								7,408	
								204	
								32,395	
								6,558	
								1,989	
							81,642	222,493	
		6,067	1,000				394,328	2,070,434	45,273
							63,674		
	\$11,895	92,978	7,737	\$22,333			134,908		24,655
	570	1,755		375					
	12,465	94,733	7,737	22,708			134,908		25,681
\$359,873	52,496	760					89,259		13,045
359,873	52,496	760					89,259		135,193
		30,512	11,116			\$14,294	70,647		12,758
		30,512	11,116			14,294	70,647		27,335
		16,458		53,087	\$121,528		17,136		
	1,371	4,343		33,567	72,267		24,330		
4,556	12,675	5,933		24,702	18,310	179	81,008		5,170
4,556	14,046	26,734		111,356	212,105	179	122,474		9,758
							5,000		
364,429	79,007	158,806	19,853	134,064	212,105	14,473	880,290	2,070,434	243,240

NIH Management Fund, Service & Supply Fund, and GSA Rent Fiscal Year 2002

(Dollars in Thousands)



DISTRIBUTION OF NCI PAYMENT	Amount	Share of NCI
Clinical Center	\$89,365	51.3%
Center for Scientific Review	7,185	4.1%
Center for Information Technology	7,615	4.4%
GSA Rental Payments for Space	32,061	18.4%
Service & Supply Fund	12,088	6.9%
Other Research Services	11,193	6.4%
Other OD	14,893	8.5%
Total Management Fund, SSF & Rent	174,400	100.0%
Other NIH Institutes Management Fund	551,361	
Total NIH Management Fund	\$725,761	

The Management Fund provides for the financing of certain common research and administrative support activities which are required in the operations of NIH:

Clinical Center: Admissions and followup, anesthesiology, diagnostic x-ray, nuclear medicine, clinical pathology, blood bank, rehabilitation medicine, pharmacy, medical records, nursing services, patient nutrition service, housekeeping services, laundry, and social work

Center for Scientific Review: Initial scientific review of applications, assignment of research grant applications to institutes

Center for Information Technology: Research and development program in which concepts and methods of computer science are applied to biomedical problems

GSA Rental Payments for Space: Building rental including utilities and guard services.

Note: This does not include all of NCI's lease payments, only those paid through the NIH Management Fund.

Other Research Services: Procurement, safety, engineering, biomedical engineering, veterinary resources, and library

Service & Supply Fund: Animal support, collaborative research, conference services, hazardous waste management, interpreting services, library, occupational health and safety, property management support, radiation safety

Special Sources of Funds

CRADAs

As a result of the Federal Technology Transfer Act of 1986 (PL 99-502), government laboratories are authorized to enter into Cooperative Research and Development Agreements (CRADAs) with private sector entities. Licensing agreements are usually incorporated into the CRADA document which addresses patent rights attributable to research supported under the CRADA.

CRADA Receipts Deposited to the U.S. Treasury
(Dollars in Thousands)

Fiscal Year	Carryover from Prior Year	Collections	Obligations
1993	\$841	\$1,779	\$1,117
1994	1,503	2,272	1,327
1995	2,448	2,811	1,395
1996	3,864	2,017	1,394
1997	4,486	13,378	6,639
1998	11,217	5,351	7,266
1999	9,302	3,645	4,707
2000	8,240	2,717	4,618
2001	6,339	5,295	2,770
2002	8,864	5,048	2,380

Royalty Income

NCI retains a portion of the royalty income generated by the patents related to NCI-funded research. A major portion of this royalty income is used to reward employees of the laboratory, further scientific exchange and for education and training in accordance with the terms of the Federal Technology Transfer Act (PL 99-502). Receipts are also used to support costs associated with processing and collecting royalty income and for technology transfer efforts in NCI and NIH.

Royalty Income Funding History
(Dollars in Thousands)

Years	Collections*	Inventor Payments	Other
1993/1994	\$5,700	\$983	\$4,717
1994/1995	11,244	1,235	10,009
1995/1996	9,031	953	8,078
1996/1997	13,598	2,175	11,423
1997/1998	9,814	2,321	7,493
1998/1999	22,716	5,084	17,632
1999/2000	21,160	4,695	16,465
2000/2001	37,040	4,811	32,229
2001/2003	27,443	6,210	21,233
2002/2004	42,565	3,961	38,604

* Does not include assessments by NIH.

Breast Cancer Emergency Supplement – Flood Money

The Emergency Supplement Appropriations Act (PL 105-18) of June 1997, appropriated \$15,000,000 to the Department of Health and Human Services to support high priority health research in the area of environmental influences on breast cancer. \$12,000,000 of the funds were transferred to NCI to support breast cancer research. In FY 1999, NCI obligated \$9,748,403, in FY 2000, NCI obligated \$215,400 and in FY 2001 NCI obligated \$2,027,729. NCI obligated the remaining \$8,468 in FY 2002.

Stamp Out Breast Cancer

The Stamp Out Breast Cancer Act (PL 105-41) was established in August 1997 and extended in July 2000 (PL 106-253). This act allows postal customers to contribute to funding for breast cancer research through their voluntary purchases of special rate postage stamps from U.S. Postal Service. The Act required the USPS to transfer 70% to NIH and 30% to the DOD of the funds collected above the postage costs and administrative costs. As of January 2003, NCI has received \$19,579,351. NCI has used these funds for research projects directed towards breast cancer, specifically, those grants in response to the NCI RFA for "Insight Awards to Stamp Out Breast Cancer." In FY 2001, 12 R21 grants were awarded. The second year of these insight awards were funded in FY 2002.

Research Funding for Various Research Areas


(Dollars in Millions)

The National Cancer Institute reports how appropriated funds are spent in a number of different categories or classifications including specific cancer sites, cancer types, diseases related to cancer, as well as types of research mechanisms. The table below represents funding levels for frequently requested research areas. These research areas do not represent the entire NCI research portfolio. Funding for these areas can overlap and do not add to the total NCI budget. For example, dollars for a clinical trial on breast cancer research would be included in both the Breast Cancer and the Clinical Trials lines in the table below. Similarly, a basic cancer research project may be relevant to cervical, uterine and ovarian cancers and relevant funding would be included in the figures for all three sites.

Disease Area	1998 Actual	1999 Actual	2000 Actual	2001 Actual	2002 Actual
Total NCI Budget	\$2,551.3	\$2,891.0	\$3,311.1	\$3,753.7	\$4,176.7
AIDS	225.9	239.2	244.1	237.8	254.4
Brain & CNS	54.3	63.5	71.9	80.7	95.2
Breast Cancer	348.7	387.2	438.7	475.2	522.6
Cervical Cancer	58.0	66.3	67.0	72.6	67.6
Colorectal Cancer	121.0	152.9	175.8	207.4	245.0
Head and Neck Cancers	41.9	45.9	47.0	50.0	58.9
Hodgkins Disease	8.3	8.2	9.4	10.2	11.8
Leukemia	103.4	122.2	141.7	154.0	177.2
Liver Cancer	38.1	39.8	46.2	54.5	62.5
Lung Cancer	139.8	151.0	175.0	206.5	237.5
Melanoma	50.3	60.1	67.9	71.8	82.3
Multiple Myeloma	10.8	15.3	18.0	19.7	20.8
Non Hodgkin's Lymphoma	57.1	66.2	70.4	79.5	85.6
Ovarian Cancer	40.8	56.5	65.5	76.9	93.5
Pancreatic Cancer	14.2	17.3	20.0	21.8	33.1
Prostate Cancer	86.9	135.7	203.2	258.0	278.4
Stomach Cancer	8.2	7.6	8.2	9.0	11.4
Uterine Cancer	12.2	13.8	16.0	18.8	23.1

Research Project Grants Number of Awards Fiscal Years 1993 - 2002

Includes Small Business Innovation Research and Small Business Technology Transfer Awards



RPGs Requested and Awarded Fiscal Years 1993 - 2002

(Dollars in Thousands)

Fiscal Year	Type	Requested		Awarded		Success Rate	
		No.	Amt.	No.	Amt.		
1993	Competing	New	3,173	\$746,912	644	\$114,227	23.9%
		Renewal	891	328,657	340	107,949	
		Supplement	75	8,554	7	1,698	
		Subtotal	4,139	1,084,123	991	223,874	
	Non-Competing			2,346	692,436		
	Total			3,337	916,310		
1994	Competing	New	3,643	\$787,824	657	\$118,403	21.1%
		Renewal	935	342,068	308	110,723	
		Supplement	20	3,311	4	733	
		Subtotal	4,598	1,133,203	969	229,859	
	Non-Competing			2,436	704,665		
	Total			3,405	934,524		
1995	Competing	New	3,345	\$789,560	645	\$119,760	23.3%
		Renewal	1,048	403,577	375	127,065	
		Supplement	21	7,502	10	1,537	
		Subtotal	4,414	1,200,639	1,030	248,362	
	Non-Competing			2,333	704,374		
	Total			3,363	952,736		
1996	Competing	New	3,071	\$733,313	682	\$142,249	27.5%
		Renewal	947	367,270	422	139,995	
		Supplement	10	1,921	5	694	
		Subtotal	4,028	1,102,504	1,109	282,938	
	Non-Competing			2,381	751,592		
	Total			3,490	1,034,530		
1997	Competing	New	3,328	\$828,653	815	\$160,763	29.2%
		Renewal	815	354,054	392	146,912	
		Supplement	14	3,136	5	755	
		Subtotal	4,157	1,185,843	1,212	308,430	
	Non-Competing			2,532	814,885		
	Total			3,744	1,123,315		
1998	Competing	New	3,054	\$797,477	847	\$189,746	32.8%
		Renewal	697	283,562	382	137,764	
		Supplement	18	4,299	6	1,421	
		Subtotal	3,769	1,085,338	1,235	328,931	
	Non-Competing			2,723	901,845		
	Total			3,958	1,230,776		
1999	Competing	New	3,905	\$1,091,110	1,088	\$237,187	31.8%
		Renewal	757	340,075	390	145,623	
		Supplement	12	3,882	6	2,353	
		Subtotal	4,674	1,435,067	1,484	385,163	
	Non-Competing			2,867	976,610		
	Total			4,351	1,361,773		
2000	Competing	New	4,116	\$1,253,002	957	\$251,628	27.2%
		Renewal	839	435,207	392	175,908	
		Supplement	11	2,379	2	231	
		Subtotal	4,966	1,690,588	1,351	427,767	
	Non-Competing			3,175	1,100,234		
	Total			4,526	1,528,001		
2001	Competing	New	4,342	\$1,374,538	1,050	\$290,707	27.3%
		Renewal	856	437,455	372	173,722	
		Supplement	29	11,108	6	1,214	
		Subtotal	5,227	1,823,101	1,428	465,643	
	Non-Competing			3,267	1,213,098		
	Total			4,695	1,678,741		
2002	Competing	New	4,539	\$1,407,475	1,142	\$302,217	28.4%
		Renewal	861	404,789	384	186,087	
		Supplement	42	8,512	21	3,499	
		Subtotal	5,442	1,820,776	1,547	491,803	
	Non-Competing			3,429	1,356,138		
	Total			4,976	1,847,941		

Includes Small Business Innovation Research and Small Business Technology Transfer Awards.

Success rate is the number of awarded grants divided by the number of awards requested.

The requested data excludes applications not recommended for further review.


In FY 2002, the total excludes Program Evaluation Dollars at \$45,273 and R21 Stamp Dollars at \$1,129.

RPG Awards by Activity Code

Fiscal Years 1993 - 2002

(Dollars in Thousands; Activity Code Descriptions on next page)

		R01	P01	R35	R37	R29	RFA	U01	R03	R21	R33	R15	R55	SBIR/ STTR	TOTAL
1993	#	1,955	176	75	166	291	282	171					6	215	3,337
	\$	430,203	202,852	61,337	51,633	29,053	63,267	56,199					1,365	20,401	916,310
1994	#	1,914	163	72	154	312	319	232	46	5			9	179	3,405
	\$	434,612	184,852	61,369	48,699	32,610	70,879	75,444	2,393	353			540	22,773	934,524
1995	#	1,808	149	67	142	342	314	253	44	34			19	191	3,363
	\$	439,122	171,524	63,032	45,125	36,014	72,409	81,771	2,488	7,640			1,126	32,485	952,736
1996	#	1,964	144	65	110	388	268	226	85	46			14	180	3,490
	\$	504,398	182,609	62,550	37,070	41,170	66,102	88,962	5,443	9,599			984	35,643	1,034,530
1997	#	2,194	149	63	90	446	195	169	101	63			21	253	3,744
	\$	583,116	202,317	62,892	30,950	47,413	48,148	81,193	6,411	12,269			1,450	47,156	1,123,315
1998	#	2,454	160	57	75	485	132	157	97	76		2	14	249	3,958
	\$	672,873	228,854	57,712	27,212	52,136	42,750	79,370	6,069	11,782		127	684	51,207	1,230,776
1999	#	2,796	169	38	71	413	261	31	108	159	6	2	6	291	4,351
	\$	775,961	249,583	38,585	27,377	45,361	112,868	21,319	7,355	22,548	2,079	200	620	57,917	1,361,773
2000	#	3,011	179	21	60	314	269	18	100	223	20	0	5	306	4,526
	\$	898,764	286,234	19,413	24,688	34,769	132,872	13,617	7,034	32,897	10,074	99	450	67,090	1,528,001
2001	#	3,231	178	1	61	210	260	18	122	231	49	3	3	328	4,695
	\$	1,008,199	301,115	2,186	26,682	23,738	150,224	14,873	9,024	42,326	23,883	358	300	75,833	1,678,741
2002	#	3,376	173	0	65	112	267	17	186	308	79	10	9	374	4,976
	\$	1,093,908	317,632	0	29,445	12,471	177,195	17,531	14,115	57,633	39,317	1,477	850	86,367	1,847,941



Activity Code Descriptions

R01	Research Project (Traditional) discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his/her specified interest and competencies.
P01	Research Program Projects broadly based, multidisciplinary, often long-term, research program which has a specific major objective or a basic theme. A program project is directed toward a range of problems having a central research focus in contrast to the usually narrower thrust of the traditional research project.
R35	Outstanding Investigator Grants long-term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential in a categorical program area.
R37	Method to Extend Research in Time (MERIT) Award long-term grant support to investigators whose research competence and productivity are distinctly superior and who are highly likely to continue to perform in an outstanding manner. Investigators may not apply for a MERIT award. Program staff and/or members of the cognizant National Advisory Council/Board will identify candidates for the MERIT award during the course of review of competing research grant applications prepared and submitted in accordance with regular PHS requirements.
R29	First Independent Research Support and Transition (FIRST) Award sufficient initial period of research support for newly independent biomedical investigators to develop their research capabilities and demonstrate the merit of their research ideas.
RFA	Request for Applications A formal statement inviting grant or cooperative agreement applications in a well-defined scientific area to accomplish specific program purposes and indicates the amount of funds set aside for the competition and/or the estimated number of awards to be made.
U01	Research Project (Cooperative Agreement) discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his/her specific interest and competencies.
R03	Small Grants research support specifically limited in time and amount for studies in categorical program areas. Small grants provide flexibility for initiating studies, which are generally for preliminary short-term projects and are non-renewable.
R21	Exploratory/Developmental Grants Phase I development of new research activities in categorical program areas. Support generally is restricted in level of support and in time.
R33	Exploratory/Developmental Grants Phase II development of new research activities in categorical program areas. Support generally is restricted in level of support and in time.
R15	Academic Research Enhancement Award (AREA) to domestic health professional schools and other institutions offering baccalaureate or advanced degrees in health sciences, except those that have received NIH research grants and/or cooperative agreements. Supports feasibility studies and other small-scale research projects.
R55	Shannon Awards limited support to scientists whose research applications fall short of the cutoff for funding yet are at the "margin of excellence" whereby the perceived quality of the grant is statistically indistinguishable from grants that are funded.
R41	Small Business Technology Transfer (STTR) Grants - Phase I establish the technical merit and feasibility of R&D ideas which may ultimately lead to a commercial product(s) or service(s).
R42	Small Business Technology Transfer (STTR) Grants - Phase II establish the technical merit and feasibility of R&D ideas which may ultimately lead to a commercial product(s) or service(s).
R43	Small Business Innovation Research (SBIR) Grants - Phase I projects limited in time and amount, to establish the technical merit and feasibility of R&D ideas which may ultimately lead to a commercial product(s) or service(s).
R44	Small Business Innovation Research (SBIR) Grants - Phase II in-depth development of R&D ideas whose feasibility has been established in Phase I and which are likely to result in commercial products or services.

Cancer Centers by State (P30 Core Grants), Fiscal Year 2002

(Dollars in Thousands)

State	Grantee Institution	Type	Amount
Alabama	University of Alabama at Birmingham	Comprehensive	\$4,790
Arizona	University of Arizona	Comprehensive	2,434
California	Beckman Research Institute	Comprehensive	757
	Burnham Institute	Lab/Basic	2,964
	Salk Institute for Biological Sciences	Lab/Basic	2,619
	University of California Davis	Clinical	1,261
	University of California Irvine	Comprehensive	1,119
	University of California Los Angeles	Comprehensive	3,332
	University of California San Diego	Clinical	4,004
	University of California San Francisco	Comprehensive	6,177
	University of Southern California	Comprehensive	5,812
Colorado	University of Colorado System	Comprehensive	3,553
Connecticut	Yale University	Comprehensive	2,079
District of Columbia	Georgetown University	Comprehensive	2,824
Florida	University of South Florida	Clinical	2,102
Hawaii	University of Hawaii at Manoa	Clinical	1,849
Illinois	Northwestern University	Comprehensive	4,395
	University of Chicago	Comprehensive	4,002
Indiana	Indiana University - Purdue University at Indianapolis	Comprehensive	1,374
	Purdue University West Lafayette	Lab/Basic	1,146
Iowa	University of Iowa	Comprehensive	1,295
Maine	Jackson Laboratory	Lab/Basic	2,508
Maryland	Johns Hopkins University	Comprehensive	6,131
Massachusetts	Dana-Farber Cancer Institute	Comprehensive	10,145
	Massachusetts Institute of Technology	Lab/Basic	2,410
Michigan	University of Michigan at Ann Arbor	Comprehensive	4,934
	Wayne State University	Comprehensive	706
Minnesota	Mayo Clinic Rochester	Clinical	3,006
	University of Minnesota Twin Cities	Comprehensive	1,319
Missouri	Washington University	Comprehensive	1,344
Nebraska	University of Nebraska Medical Center	Lab/Basic	1,137
New Hampshire	Dartmouth College	Comprehensive	1,780
New Jersey	Univ of Med/Dent NJ Newark	Clinical	2,516
New York	American Health Foundation	Lab/Basic	2,554
	Cold Spring Harbor Laboratory	Lab/Basic	3,634
	Columbia University Health Sciences	Comprehensive	3,968
	Roswell Park Cancer Institute Corp	Comprehensive	1,226
	Sloan-Kettering Institute for Cancer Research	Comprehensive	6,145
	Yeshiva University	Comprehensive	3,768
North Carolina	Duke University	Comprehensive	5,609
	University of North Carolina Chapel Hill	Comprehensive	5,160
	Wake Forest University	Comprehensive	1,436
Ohio	Case Western Reserve University	Comprehensive	3,834
	Ohio State University	Comprehensive	2,517
Oregon	Oregon Health & Science University	Clinical	1,203
Pennsylvania	Fox Chase Cancer Center	Comprehensive	7,515
	Thomas Jefferson University	Clinical	4,386
	University of Pennsylvania	Comprehensive	5,257
	University of Pittsburgh at Pittsburgh	Comprehensive	3,964
	Wistar Institute	Lab/Basic	2,379
Tennessee	St. Jude Children's Research Hospital	Clinical	4,702
	Vanderbilt University	Clinical	2,983
Texas	CTRC Research Foundation	Comprehensive	3,214
	University of Texas M.D. Anderson Cancer Center	Comprehensive	5,745
Utah	University of Utah	Clinical	1,359
Vermont	University of Vermont & St. Agric College	Comprehensive	1,266
Virginia	University of Virginia Charlottesville	Clinical	1,943
	Virginia Commonwealth University	Clinical	1,788
Washington	Fred Hutchinson Cancer Research Center	Comprehensive	7,036
Wisconsin	University of Wisconsin Madison	Comprehensive	5,266
	Total P30s	60	197,678
	Total Planning Grants (P20s)		6,715
	Total Clinical Core Grants (P40/P41/U42)		222
	NCI Co-funded Awards with other NIH Institutes		3,394

Total Cancer Centers

\$208,009

Specialized Programs of Research Excellence, Fiscal Year 2002

(Dollars in Thousands)

In 1992, the NCI established the Specialized Programs of Research Excellence (SPORE). This program promotes interdisciplinary research and speeds the bidirectional exchange between basic and clinical science to move basic research findings from the laboratory to applied settings involving patients and populations. The goal of the SPORE program is to bring to clinical care settings novel ideas that have the potential to reduce cancer incidence and mortality, and to improve survival, and the quality of life.


Laboratory and clinical scientists work collaboratively to plan, design and implement research programs that impact on cancer prevention, detection, diagnosis, treatment and control. To facilitate this research, each SPORE develops and maintains specialized resources that benefit all scientists working on the specific cancer site, as well as SPORE scientists. An additional SPORE element is a career development program that recruits scientists both within and outside the SPORE institution to enlarge the cadre of laboratory and clinical scientists dedicated to translational research on human cancer. SPOREs meet annually to share data, assess research progress, identify new research opportunities and establish research priorities.

Mechanism	Site	No.	Amount
SPOREs	Bladder	1	\$2,972
	Brain	2	3,881
	Breast	7	16,645
	Gastrointestinal	5	9,273
	Head and Neck	3	3,058
	Lung	6	15,087
	Lymphoma	2	4,318
	Ovarian	4	9,964
	Prostate	11	24,862
	Skin	2	4,091
	Total P50	43	94,151
Supplements	Miscellaneous Supplements	0	215
Co-funded	Urology with NIDDK	0	531
Total		43	\$94,897

NRSA Predoctoral and Postdoctoral Trainees


Fiscal Years 1993 - 2002

(Full Time Trainee Positions)



Construction/Renovation Funding Fiscal Years 1993 - 2002

(Dollars in Thousands)



	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
■ Grants	\$7,182	\$15,447	\$6,570	\$1,500	\$1,410	\$1,461	\$958	\$1,488	\$1,500	\$1,500
■ Contracts	346	1,002	1,430	1,500	1,590	1,500	2,042	2,012	1,500	3,500
Total	7,528	16,449	8,000	3,000	3,000	2,961	3,000	3,500	3,000	5,000

Grant and Contract Awards by State Fiscal Year 2002

(Dollars in Thousands)

State	Grants		Contracts		Total NCI		State
	No	Amount	No	Amount	No	Amount	
Alabama	83	\$39,356	12	\$8,259	95	\$47,615	Alabama
Alaska	2	1,334	0	0	2	1,334	Alaska
Arizona	83	39,429	2	469	85	39,899	Arizona
Arkansas	15	7,638	0	0	15	7,638	Arkansas
California	861	423,528	32	176,049	893	599,577	California
Colorado	118	34,092	2	3,271	120	37,363	Colorado
Connecticut	83	26,736	3	3,035	86	29,772	Connecticut
Delaware	5	1,411	0	0	5	1,411	Delaware
District of Columbia	78	36,846	18	18,168	96	55,014	District of Columbia
Florida	110	33,497	2	2,267	112	35,764	Florida
Georgia	65	20,429	14	6,995	79	27,424	Georgia
Hawaii	18	13,817	3	3,673	21	17,490	Hawaii
Idaho	0	0	0	0	0	0	Idaho
Illinois	195	81,959	18	6,208	213	88,168	Illinois
Indiana	62	18,788	0	0	62	18,788	Indiana
Iowa	44	16,031	4	4,817	48	20,847	Iowa
Kansas	25	9,447	5	2,411	30	11,858	Kansas
Kentucky	40	10,412	4	4,447	44	14,859	Kentucky
Louisiana	30	6,398	1	381	31	6,778	Louisiana
Maine	10	4,574	0	0	10	4,574	Maine
Maryland	217	97,050	70	100,014	287	197,064	Maryland
Massachusetts	635	285,530	4	2,646	639	288,176	Massachusetts
Michigan	195	74,848	8	14,995	203	89,843	Michigan
Minnesota	158	72,383	6	6,464	164	78,847	Minnesota
Mississippi	3	430	0	0	3	430	Mississippi
Missouri	111	35,841	9	7,164	120	43,004	Missouri
Montana	4	549	0	0	4	549	Montana
Nebraska	34	12,181	0	0	34	12,181	Nebraska
Nevada	6	2,093	0	0	6	2,093	Nevada
New Hampshire	46	21,943	1	174	47	22,117	New Hampshire
New Jersey	103	35,359	4	2,751	107	38,110	New Jersey
New Mexico	29	11,806	3	1,761	32	13,567	New Mexico
New York	623	257,245	13	6,657	636	263,902	New York
North Carolina	246	106,663	12	6,394	258	113,057	North Carolina
North Dakota	2	842	0	0	2	842	North Dakota
Ohio	272	84,855	17	6,882	289	91,738	Ohio
Oklahoma	17	3,604	1	79	18	3,684	Oklahoma
Oregon	53	17,988	0	0	53	17,988	Oregon
Pennsylvania	473	251,314	12	9,305	485	260,619	Pennsylvania
Rhode Island	44	13,382	0	0	44	13,382	Rhode Island
South Carolina	35	9,012	0	0	35	9,012	South Carolina
South Dakota	4	3,165	0	0	4	3,165	South Dakota
Tennessee	162	68,467	2	106	164	68,572	Tennessee
Texas	420	203,906	11	6,078	431	209,984	Texas
Utah	47	19,910	2	2,935	49	22,845	Utah
Vermont	18	9,199	1	17	19	9,217	Vermont
Virginia	85	27,456	9	3,092	94	30,547	Virginia
Washington	267	131,615	4	4,918	271	136,533	Washington
West Virginia	5	1,076	1	1,441	6	2,518	West Virginia
Wisconsin	118	41,235	3	2,802	121	44,038	Wisconsin
Wyoming	3	280	0	0	3	280	Wyoming
Total	6,362	2,726,951	313	427,129	6,675	3,154,080	Total
Puerto Rico	2	1,178	0	0	2	1,178	Puerto Rico
Total	6,364	2,728,129	313	427,129	6,677	3,155,258	Total

Excludes NRSA TAP, Foreign Contracts and Grants, and Program Evaluation.

Grant and Contract Awards by Country Fiscal Year 2002

(Dollars in Thousands)

Country	Grant		Contract		Total NCI		Country
	No	Amount	No	Amount	No	Amount	
Argentina	0	\$18				\$18	Argentina
Australia	17	4,607			17	4,607	Australia
Belgium	1	439	1	\$53	2	491	Belgium
Brazil	0	61				61	Brazil
Canada	20	7,527	2	145	22	7,673	Canada
China			1	40	1	40	China
Costa Rica			1	60	1	60	Costa Rica
Denmark			1	15	1	15	Denmark
Finland			1	200	1	200	Finland
France	3	606			3	606	France
Germany			1	74	1	74	Germany
India	1	206			1	206	India
Israel	6	834			6	834	Israel
Italy			1	308	1	308	Italy
Japan			1	157	1	157	Japan
Mexico	0	18				18	Mexico
Netherlands	1	97			1	97	Netherlands
New Zealand			2	170	2	170	New Zealand
Peru	0	10				10	Peru
Poland			1	772	1	772	Poland
South Africa	1	228			1	228	South Africa
Spain	1	180			1	180	Spain
Sweden	2	391	2	54	4	445	Sweden
Uganda	0	28				28	Uganda
United Kingdom	3	551			3	551	United Kingdom
West Indies			1	685	1	685	West Indies
Total Foreign	56	\$15,800	16	\$2,732	72	\$18,532	

Institutions Receiving More than \$15 Million in NCI Support, FY 2002

(Dollars in Thousands)

State	Institution	Grants	Contracts	Total NCI
Alabama	University of Alabama at Birmingham	\$32,504	\$5,937	\$38,441
Arizona	University of Arizona	34,448	469	34,917
California	Burnham Institute	18,456		18,456
	Foundation for the Children's Oncology Group	28,580		28,580
	Science Applications International Corporation		149,083	149,083
	Scripps Research Institute	22,042	996	23,038
	Stanford University	37,740		37,740
	University of California System	175,458	3,380	178,838
	University of Southern California	41,185	3,021	44,206
Colorado	University of Colorado Health Sciences Center	21,263	2,160	23,423
Connecticut	Yale University	21,511	1,261	22,772
Dist of Columbia	Georgetown University	13,974	1,586	15,560
Florida	University of South Florida	17,380		17,380
Illinois	Northwestern University	21,937		21,937
	University of Chicago	31,898	1,318	33,216
	University of Illinois	15,972	1,237	17,209
Iowa	University of Iowa	13,385	4,817	18,202
Maryland	Johns Hopkins University	69,733	3,074	72,807
Massachusetts	Beth Israel Deaconess Medical Center	16,011		16,011
	Brigham & Women's Hospital	36,231	100	36,331
	Dana-Faber Cancer Institute	56,844		56,844
	Frontier Science & Technology Research FDN, Inc.	15,615		15,615
	Harvard University	36,324		36,324
	Massachusetts General Hospital	35,297	577	35,874
	University of Massachusetts	16,326		16,326
Michigan	University of Michigan	52,037	4,448	56,485
	Wayne State University	13,788	5,530	19,318
Minnesota	Mayo Clinic Rochester	46,100	1,014	47,114
	University of Minnesota	23,247	5,450	28,697
Missouri	Washington University	25,293	3,139	28,432
New Hampshire	Dartmouth College	20,330	174	20,504
New York	Columbia University	28,724		28,724
	Mount Sinai School of Medicine	20,241		20,241
	New York University	36,927		36,927
	Roswell Park Cancer Institute Corp	21,595		21,595
	Sloan-Kettering Institute for Cancer Research	54,658	2,264	56,922
	Yeshiva University	27,858		27,858
North Carolina	Duke University	54,124	1,305	55,429
	University of North Carolina Chapel Hill	35,623		35,623
Ohio	Case Western Reserve University	30,774		30,774
	Ohio State University	25,530	1,885	27,415
Pennsylvania	American College of Radiology	29,034		29,034
	Fox Chase Cancer Center	25,581	4,378	29,959
	NSABP Foundation, Inc.	27,420		27,420
	Thomas Jefferson University	21,655	688	22,343
	University of Pennsylvania	59,796	1,276	61,072
	University of Pittsburgh at Pittsburgh	38,485	2,963	41,448
Tennessee	St. Jude Children's Research Hospital	23,771		23,771
	Vanderbilt University	39,101		39,101
Texas	Baylor College of Medicine	35,491	213	35,704
	CTRC Research Foundation	37,198		37,198
	University of Texas	116,753	5,032	121,785
Utah	University of Utah	19,151	2,935	22,086
Virginia	University of Virginia Charlottesville	15,283		15,283
Washington	Fred Hutchinson Cancer Research Center	79,772	4,433	84,205
	University of Washington	29,637	385	30,022
Wisconsin	University of Wisconsin Madison	33,208	1,299	34,507
	Total	\$1,978,299	\$227,827	\$2,206,125

Includes Manpower Development Grants

Appropriations of the NCI 1938-2002

(In Whole Dollars)

1938 - 1969	\$1,875,699,720	
1970 - 1979	6,073,870,500	
1980 - 1989	11,958,860,000	
1990.....	1,664,000,000	<i>prior to reductions in PL 101-166 (-\$6,839,000) and PL101-239 (-\$22,829,000).</i>
1991.....	1,766,324,000	<i>prior to reductions in PL 101-517 (-\$8,972,000 for salary and expense reduction; -\$42,568,000 for across-the-board reduction).</i>
1992.....	1,989,278,000	<i>prior to reductions in PL 102-170 (-\$21,475,000 for salary and expense reduction; -\$1,262,000 for travel reduction; \$15,000,000 transferred to other institutes for cancer research).</i>
1993.....	2,007,483,000	<i>prior to reductions in PL 102-294 (-\$16,060,000 for .8% reduction to all line items, -\$9,933,000 for S&E reduction, -\$139,000 for consultant services reduction).</i>
1994.....	2,082,267,000	<i>prior to reduction in PL103-211 (-\$5,885,000 administration reduction).</i>
1995.....	2,135,119,000	<i>prior to reductions in PL 103-211 (-\$1,883,000 for Procurement reduction; -\$116,000 for SLUC reduction; -\$1,052,000 for Bonus Pay reduction). Includes \$218,199,000 of AIDS funding.</i>
1996.....	2,251,084,000	<i>Includes \$225,790,000 of AIDS funding.</i>
1997.....	2,382,532,000	<i>Includes \$224,983,000 of AIDS funding.</i>
1998.....	2,547,314,000	<i>prior to reductions in PL 105-119 (-\$4,755,000 via the Secretary's 1% transfer authority). Includes \$8,699,000 transferred via the NIH Director's 1% transfer authority, \$41,000 transfer from U.S. Dept of State in PL 105-119, and \$226,414,000 of AIDS funding.</i>
1999.....	2,927,187,000	<i>prior to reductions in PL 106-51 (-\$1,940,000 for travel and admin expenses). Includes -\$931,000 transferred via the Secretary 1% transfer authority, and -\$6,259,000 transferred via the NIH Director's 1% transfer authority, and \$239,190,000 of AIDS funding.</i>
1990 - 1999	21,752,588,000	
2000.....	3,332,317,000	<i>prior to reductions in PL 106-113 (-\$17,763,000 for across the board reduction). Includes \$245,804,000 of AIDS funding.</i>
2001.....	3,757,242,000	<i>prior to reductions in PL 106-554(-\$2,005,000 for across the board reduction). Includes -\$711,000 Secretary's 1% transfer, -\$781,000 transfer for Office of Human Research Protection and -\$24,000 lapse. Includes \$255,960,000 of AIDS funding.</i>
2002.....	4,190,405,000	<i>prior to reductions in PL 107-116(-\$4,524,000 via the Secretary's 1% transfer authority, -\$2,054,000 for the enacted rescission, -\$7,118,000 administrative reduction and -\$8,000 lapse). Includes \$254,396,000 of AIDS funding.</i>
1938-2002	52,940,982,220	


By-Pass Budget Requests Fiscal Years 1973-2004

(In Whole Dollars)

Fiscal Year	Request
1973.....	\$550,790,000
1974.....	640,031,000
1975.....	750,000,000
1976.....	898,500,000
1977.....	948,000,000
1978.....	955,000,000
1979.....	1,036,000,000
1980.....	1,055,000,000
1981.....	1,170,000,000
1982.....	1,192,000,000
1983.....	1,197,000,000
1984.....	1,074,000,000
1985.....	1,189,000,000
1986.....	1,460,000,000
1987.....	1,570,000,000
1988.....	1,700,000,000
1989.....	2,080,000,000
1990.....	2,195,000,000
1991.....	2,410,000,000
1992.....	2,612,000,000
1993.....	2,775,000,000
1994.....	3,200,000,000
1995.....	3,600,000,000
1996.....	3,640,000,000
1997.....	2,977,000,000
1998.....	2,702,500,000
1999.....	3,191,000,000
2000.....	3,873,000,000
2001.....	4,135,000,000
2002.....	5,030,000,000
2003.....	5,690,000,000
2004.....	5,986,000,000

The National Cancer Act in December 1971, included a provision for the Director, NCI to submit an annual budget request directly to the President, with comment only by NIH and DHHS. This Bypass Budget was first submitted for 1973.

Bypass Requests and Appropriations of the NCI Fiscal Years 1973-2004





Comparison of Dollars, Positions and Space Fiscal Years 1992-2002

Funds are obligations against the annual appropriation in millions of dollars

FTEs are the number of workyears for appointed employees of the NCI. A workyear equals 2,080 hours.

The increase in FTEs in FY 2000 is due to the fact that 195 contract staff were converted to NCI appointments.

Space is in thousands of square feet, excluding NCI-Frederick.



Personnel Resources Fiscal Years 1995-2002

Fiscal Year	Full Time Appointment	Part Time Appointment	Training Fellows	Total Personnel Resources
1995	1,767	483	1,055	3,305
1996	1,841	460	960	3,261
1997	1,915	422	1,023	3,360
1998	1,921	466	1,124	3,511
1999	1,941	628	1,060	3,629
2000	2,139	831	1,202	4,172
2001	2,224	912	963	4,099
2002	2,250	979	949	4,178

AIDS Funding History

Fiscal Years 1992-2002

(Dollars in Thousands)

Fiscal Year	NCI	NIH	% NCI of NIH
1992	\$165,668	\$1,047,294	16%
1993	173,029	1,073,957	16%
1994	212,868	1,298,996	16%
1995	217,430	1,333,600	16%
1996	225,360	1,411,860	16%
1997	224,733	1,501,073	15%
1998	225,991	1,559,071	14%
1999	239,190	1,797,422	13%
2000	244,145	2,005,100	12%
2001	237,789	2,244,160	11%
2002	254,396	2,500,866	10%

